Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Gynecol Oncol
    November 2024
  1. SHU T, Liang Y, Zhang S, Sun T, et al
    The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer.
    Gynecol Oncol. 2024;192:94-101.
    >> Share

  2. BORHO L, Elishaev E, Bao R, O'Brien E, et al
    Association of neighborhood social vulnerability with ovarian cancer survival.
    Gynecol Oncol. 2024;192:32-39.
    >> Share

  3. KLEPPE A, Lindemann K, Kildal W, Tobin KAR, et al
    Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer.
    Gynecol Oncol. 2024;192:80-88.
    >> Share

  4. CLASSEN CC, Chivers ML, Brotto LA, Barbera L, et al
    A randomized controlled trial of an online support group addressing psychosexual distress among women treated for gynecologic cancer.
    Gynecol Oncol. 2024;192:73-79.
    >> Share

  5. SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al
    Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.
    Gynecol Oncol. 2024;192:65-72.
    >> Share

  6. KHADRAOUI W, Sinnott JA, Meade CE, Plascak J, et al
    Clinical trial enrollment during first course of gynecologic cancer treatment and survival.
    Gynecol Oncol. 2024;192:59-64.
    >> Share

  7. MULUGETA-GORDON L, Smith AJB
    Insurance coverage and access to gynecologic oncology: Where are we are now.
    Gynecol Oncol. 2024;192:56-58.
    >> Share

  8. FRANCIS KE, Simon S, Gebski V, Joly F, et al
    Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
    Gynecol Oncol. 2024;192:50-55.
    >> Share

  9. POWELL MA, Cibula D, O'Malley DM, Boere I, et al
    Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
    Gynecol Oncol. 2024;192:40-49.
    >> Share

  10. COLEMAN RL, Lubinga SJ, Shen Q, Walder L, et al
    Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
    Gynecol Oncol. 2024;192:24-31.
    >> Share

  11. DE JAEGHERE EA, Hamerlinck H, Tuyaerts S, Lippens L, et al
    Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
    Gynecol Oncol. 2024;191:275-286.
    >> Share

  12. VREDE SW, Van Weelden WJ, Bulten J, Gilks CB, et al
    Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer.
    Gynecol Oncol. 2024;192:15-23.
    >> Share

  13. MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al
    Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile.
    Gynecol Oncol. 2024;192:8-14.
    >> Share

  14. HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al
    What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
    Gynecol Oncol. 2024;192:1-7.
    >> Share

  15. KILOWSKI KA, Dietrich MF, Xiu J, Baca Y, et al
    KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
    Gynecol Oncol. 2024;191:299-306.
    >> Share

  16. LEE AW, Poynor V, Siddiqui S
    Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020.
    Gynecol Oncol. 2024;191:292-298.
    >> Share

  17. BOITANO TKL, Blank SV, Havrilesky LJ, Huh WK, et al
    Too much of a good thing? Projecting the need for gynecologic oncologists over the next 20 years.
    Gynecol Oncol. 2024;191:287-291.
    >> Share

  18. JAIN D, Zaeim F, Wahidi M, Smith WJ, et al
    Cervical squamous cell carcinoma outcomes across continents: A retrospective study.
    Gynecol Oncol. 2024;190:272-282.
    >> Share

  19. PROPPE L, Jaeger A, Goy Y, Petersen C, et al
    Systematic review - Adjuvant radiotherapy of the vulva in primary vulvar cancer.
    Gynecol Oncol. 2024;190:264-271.
    >> Share

  20. CHOI YK, Lee JH, Kim YS, Wee CW, et al
    Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03.
    Gynecol Oncol. 2024;190:222-229.
    >> Share

  21. SHIBATA M, Yoshida K, Yokoi A, Suzuki H, et al
    Elucidation of the role of XBP1 in the progression of complete hydatidiform mole to invasive mole through RNA-seq.
    Gynecol Oncol. 2024;190:189-199.
    >> Share

  22. NONZEE NJ, Thiel de Bocanegra H, Navarro S, Bastani R, et al
    Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women.
    Gynecol Oncol. 2024;190:160-166.
    >> Share

  23. HEUS C, Stelten S, Kenter GG, Buffart LM, et al
    Body composition and peri- and postoperative complications in patients with gynaecological malignancies: A systematic review.
    Gynecol Oncol. 2024;190:131-138.
    >> Share

  24. WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al
    Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.
    Gynecol Oncol. 2024;190:124-130.
    >> Share

  25. METCALF CA, Page CE, Stocker BOS, Johnson RL, et al
    Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.
    Gynecol Oncol. 2024;190:62-69.
    >> Share

  26. MERTEN R, Strnad V, Karius A, Lotter M, et al
    Brachytherapy in vaginal cancer for organ preservation: Clinical outcome and safety from a single center experience.
    Gynecol Oncol. 2024;190:35-41.
    >> Share

  27. TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al
    Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.
    Gynecol Oncol. 2024;190:18-27.
    >> Share

  28. BROWN J
    Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit - That's a relief!
    Gynecol Oncol. 2024;190:A1-A2.
    >> Share

    October 2024
  29. VER HOEVE ES, Rumble ME, Gorzelitz JS, Rose SL, et al
    Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial cancer survivors.
    Gynecol Oncol. 2024;191:265-274.
    >> Share

  30. HUNSBERGER KS, Tewari KS, Monk BJ, Chase DM, et al
    Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:259-264.
    >> Share

  31. MOORE KN, Lorusso D, Oaknin A, Oza A, et al
    Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
    Gynecol Oncol. 2024;191:249-258.
    >> Share

  32. PENG S, Zheng Y, Liu J, Chen S, et al
    Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection.
    Gynecol Oncol. 2024;191:240-248.
    >> Share

  33. GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
    Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
    Gynecol Oncol. 2024;191:233-239.
    >> Share

  34. NAGASE Y, Matsuo K, Nakao Y, Hisa T, et al
    Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:219-227.
    >> Share

  35. LI G, Li X, Yin R, Feng M, et al
    Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
    Gynecol Oncol. 2024;191:165-171.
    >> Share

  36. HICKEY M, Trainer AH, Krejany EO, Brand A, et al
    What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).
    Gynecol Oncol. 2024;191:201-211.
    >> Share

  37. HAIGHT PJ, Lammers S, Kistenfeger Q, Leipold C, et al
    Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?
    Gynecol Oncol. 2024;191:194-200.
    >> Share

  38. YONEMORI K, Boni V, Min KG, Meniawy TM, et al
    Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
    Gynecol Oncol. 2024;191:172-181.
    >> Share

  39. ELAYAPILLAI SP, Dogra S, Lausen J, Parker M, et al
    ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer.
    Gynecol Oncol. 2024;191:182-193.
    >> Share

  40. PLINSINGA ML, Rye S, Jones T, Vagenas D, et al
    Mild symptoms matter: Results from a prospective, longitudinal study on the relationship between symptoms, lymphedema and health-related outcomes post-gynecological cancer.
    Gynecol Oncol. 2024;191:158-164.
    >> Share

  41. PERRONE E, Capasso I, Giannarelli D, Trozzi R, et al
    Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis.
    Gynecol Oncol. 2024;191:150-157.
    >> Share

  42. OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al
    Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
    Gynecol Oncol. 2024;191:124-131.
    >> Share

  43. SAAB R, Fellman BM, Legarreta AF, Meyer LA, et al
    Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study.
    Gynecol Oncol. 2024;191:143-149.
    >> Share

  44. PINTO P, Moro F, Alcazar JL, Alessi S, et al
    Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).
    Gynecol Oncol. 2024;191:132-142.
    >> Share

  45. KONG W, Deng B, Shen X, John C, et al
    Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer.
    Gynecol Oncol. 2024;191:116-123.
    >> Share

  46. NG ZY, Manchanda R, Lopez A, Obermair A, et al
    The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.
    Gynecol Oncol. 2024;191:95-99.
    >> Share

  47. CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
    Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.
    Gynecol Oncol. 2024;191:86-94.
    >> Share

  48. RUSHTON T, Krause HB, Samec T, Elliott A, et al
    Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;191:80-85.
    >> Share

  49. LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
    Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
    Gynecol Oncol. 2024;191:74-79.
    >> Share

  50. BRITTON MC, Izampuye E, Clark M, Ornstein RA, et al
    Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study.
    Gynecol Oncol. 2024;191:67-73.
    >> Share

  51. VAZ J, Piver R, Brzezinska B, Suhner J, et al
    Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomes.
    Gynecol Oncol. 2024;189:129-136.
    >> Share

    September 2024
  52. WAN S, Gao Y, Wu S, Wang H, et al
    Somatic mutation of targeted sequencing identifies risk stratification in advanced ovarian clear cell carcinoma.
    Gynecol Oncol. 2024;191:56-66.
    >> Share

  53. LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al
    Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.
    Gynecol Oncol. 2024;191:45-55.
    >> Share

  54. PRAISS AM, Dagher C, Zhou Q, Iasonos A, et al
    Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping.
    Gynecol Oncol. 2024;191:37-44.
    >> Share

  55. YANG X, Li C, Li Z, Du D, et al
    The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or interstitial brachytherapy for cervical Cancer.
    Gynecol Oncol. 2024;191:31-36.
    >> Share

  56. LI X, Argenta PA, Brown K, Honeyfield K, et al
    Associations of cytomegalovirus infection with cancer-related cognitive impairment and peripheral neuropathy in ovarian cancer survivors.
    Gynecol Oncol. 2024;191:25-30.
    >> Share

  57. JANG EB, Lee AJ, So KA, Lee SJ, et al
    Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
    Gynecol Oncol. 2024;191:19-24.
    >> Share

  58. ANASTASIO MK, Nolin A, Penvose KN, Lambert K, et al
    Adjuvant therapy and recurrence risk in non-myoinvasive high-grade (stage IC) endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:10-18.
    >> Share

  59. NIEF CA, Long SE, McCleary TL, Kidd E, et al
    Diabetes mellitus complications associated with recurrence of stage I endometrioid endometrial cancer: A single-center retrospective study.
    Gynecol Oncol. 2024;190:298-306.
    >> Share

  60. MOUFARRIJ S, Gazzo A, Rana S, Selenica P, et al
    Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification.
    Gynecol Oncol. 2024;191:1-9.
    >> Share

  61. FULLERTON R, Martell K, Khanolkar R, Phan T, et al
    Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy.
    Gynecol Oncol. 2024;190:291-297.
    >> Share

  62. BROWN J, Miller A, Holman LL, Backes F, et al
    Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
    Gynecol Oncol. 2024;190:283-290.
    >> Share

  63. NAHSHON C, Leitao MM Jr, Segev Y
    Response to the letter to the editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review".
    Gynecol Oncol. 2024;190:262-263.
    >> Share

  64. ADJEI NN, Haas A, Zhao H, Primm KM, et al
    Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021.
    Gynecol Oncol. 2024;190:255-261.
    >> Share

  65. NGUYEN L, Chung TH, Le YL, Reygaerts H, et al
    Hispanic individuals' cervical cancer screening disparities amidst the COVID-19 pandemic.
    Gynecol Oncol. 2024;190:243-249.
    >> Share

  66. RIOS-DORIA E, Nobre SP, Sassine D, Glaser G, et al
    Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium.
    Gynecol Oncol. 2024;190:236-242.
    >> Share

  67. MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al
    Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2024;190:230-235.
    >> Share

  68. YOUNG AN, Lin LH, Abel MK, Badhey MO, et al
    Atypical placental site nodules: Clinicopathologic features, management and patient outcomes in an institutional series.
    Gynecol Oncol. 2024;190:215-221.
    >> Share

  69. POTHURI B, Sawaged Z, Karpel HC, Li X, et al
    A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.
    Gynecol Oncol. 2024;190:209-214.
    >> Share

  70. PIFER PM, Kilar CR, Beriwal S
    Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment?
    Gynecol Oncol. 2024;188:A1-A3.
    >> Share

  71. WALL JA, Pozzar RA, Enzinger AC, Tavormina A, et al
    Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis.
    Gynecol Oncol. 2024;188:125-130.
    >> Share

  72. WILKE RN, Iniesta MD, Fellman B, Jazaeri AA, et al
    A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery?
    Gynecol Oncol. 2024;188:120-124.
    >> Share

  73. MONK BJ, Tewari KS, Randall LM, Pothuri B, et al
    Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
    Gynecol Oncol. 2024;188:81-82.
    >> Share

  74. LAMBERT KA, Albright BB, Anastasio MK, Kaplan SJ, et al
    Scalp hypothermia to reduce chemotherapy-induced alopecia: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;188:71-80.
    >> Share

  75. WILHITE AM, Wu S, Xiu J, Gibney GT, et al
    A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
    Gynecol Oncol. 2024;188:13-21.
    >> Share

  76. POZZAR RA, Enzinger AC, Howard C, Tavormina A, et al
    Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
    Gynecol Oncol. 2024;188:1-7.
    >> Share

    August 2024
  77. LIM H, Kim SI, Kim MK, Yoon SH, et al
    Initial sarcopenia and body composition changes as prognostic factors in cervical cancer patients treated with concurrent chemoradiation: An artificial intelligence-based volumetric study.
    Gynecol Oncol. 2024;190:200-208.
    >> Share

  78. MILLER EA, Chowdhary B, Chapman-Davis E
    Beyond the decision: Reproductive justice and cervical cancer care in a post-Dobbs era.
    Gynecol Oncol. 2024;190:186-188.
    >> Share

  79. MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al
    Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.
    Gynecol Oncol. 2024;190:146-152.
    >> Share

  80. FRICOVA L, Kommoss S, Scambia G, Ferron G, et al
    Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study.
    Gynecol Oncol. 2024;190:179-185.
    >> Share

  81. QI C, Lyu M, Yao Z, Zhang F, et al
    SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-beta/Smad pathway.
    Gynecol Oncol. 2024;190:167-178.
    >> Share

  82. CHUK E, Conway JL, Hanuschak J, Han K, et al
    Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy.
    Gynecol Oncol. 2024;190:153-159.
    >> Share

  83. KATO MK, Fujii E, Yamaguchi M, Higuchi D, et al
    Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma.
    Gynecol Oncol. 2024;190:139-145.
    >> Share

  84. BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al
    The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
    Gynecol Oncol. 2024;190:119-123.
    >> Share

  85. YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al
    Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
    Gynecol Oncol. 2024;190:113-118.
    >> Share

  86. SKOF E, Stegel V, Dragos VS, Blatnik A, et al
    Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.
    Gynecol Oncol. 2024;190:104-112.
    >> Share

  87. LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al
    Quality of life and survivorship in patients with low-grade ovarian cancer.
    Gynecol Oncol. 2024;190:96-103.
    >> Share

  88. KOTSOPOULOS J, Lubinski J, Huzarski T, Bychkovsky BL, et al
    Incidence of endometrial cancer in BRCA mutation carriers.
    Gynecol Oncol. 2024;189:148-155.
    >> Share

  89. WAGAR MK, Patel UJ, Bharucha K, Heisler CA, et al
    Postoperative urinary retention by void trial methodology following radical hysterectomy for cervical cancer.
    Gynecol Oncol. 2024;190:90-95.
    >> Share

  90. GUERRA RA, Kaplan C, Borno H, Boscardin J, et al
    The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy.
    Gynecol Oncol. 2024;190:84-89.
    >> Share

  91. SUZUKI Y, Chen L, Matsuo K, Ferris JS, et al
    Weight-loss therapy in patients with obesity with endometrial intraepithelial neoplasia and uterine cancer.
    Gynecol Oncol. 2024;190:78-83.
    >> Share

  92. GAMBLE CR, Huang Y, Quinn J, Melamed A, et al
    Neighborhood economic vulnerability as a predictor for patterns of care and outcomes for patients with uterine cancer.
    Gynecol Oncol. 2024;190:70-77.
    >> Share

  93. ROSS TL, Na R, Au-Yeung G, DeFazio A, et al
    Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
    Gynecol Oncol. 2024;190:53-61.
    >> Share

  94. YOKOI A, Machida H, Shimada M, Mastuo K, et al
    Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;190:42-52.
    >> Share

  95. GU Y, Liu Y, Cheng H, Wang W, et al
    Clinicopathological characteristics and oncologic outcomes of patients with gestational trophoblastic neoplasia manifesting as isolated pulmonary lesions.
    Gynecol Oncol. 2024;190:28-34.
    >> Share

  96. CUN HT, Bernard L, Lande KT, Lawson BC, et al
    Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
    Gynecol Oncol. 2024;189:138-145.
    >> Share

  97. FROEDING LP, Jensen PT
    Commentary on "Simple versus radical hysterectomy in women with low-risk cervical cancer" by Plante M. et al. published in The New England Journal of Medicine.
    Gynecol Oncol. 2024;189:137.
    >> Share

  98. OSTBY SA, Narasimhulu D, Ochs Kinney MA, Cliby W, et al
    Defining optimal perioperative analgesia in patients undergoing laparotomy for advanced gynecologic malignancy: A randomized controlled trial.
    Gynecol Oncol. 2024;190:11-17.
    >> Share

  99. RIEDINGER CJ, Sakach J, Maples JM, Fulton J, et al
    Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist.
    Gynecol Oncol. 2024;190:1-10.
    >> Share

  100. HOLTZMAN S, Gellman C, Kaplowitz E, Barber E, et al
    Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021.
    Gynecol Oncol. 2024;189:125-128.
    >> Share

  101. CHELSEA NN, Posever N, Hsieh TYJ, Patterson S, et al
    Implementation of a financial navigation program in gynecologic oncology.
    Gynecol Oncol. 2024;189:119-124.
    >> Share

  102. VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al
    Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
    Gynecol Oncol. 2024;189:111-118.
    >> Share

  103. GLASER S, Han E
    Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer.
    Gynecol Oncol. 2024;187:A1-A2.
    >> Share

  104. STROOT IAS, Bart J, Hollema H, Jalving M, et al
    Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
    Gynecol Oncol. 2024;187:198-203.
    >> Share

  105. WAGAR MK, Naik A, Zhang RC, Godecker A, et al
    Incidence of postoperative venous thromboembolism in patients with vulvar carcinoma undergoing vulvectomy with or without lymphadenectomy.
    Gynecol Oncol. 2024;187:192-197.
    >> Share

  106. DEL VALLE D, Ruiz R, Lekuona A, Cobas P, et al
    Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer.
    Gynecol Oncol. 2024;187:145-150.
    >> Share

  107. VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al
    Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2024;187:113-119.
    >> Share

  108. ADOLPH L, Mann A, Liu XQ, Roberts L, et al
    Follow-up of women with cervical adenocarcinoma in situ treated by conization: A single centre clinical experience.
    Gynecol Oncol. 2024;187:74-79.
    >> Share

  109. VUE NC, Sassani J, Prairie B, Yin Y, et al
    Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer.
    Gynecol Oncol. 2024;187:58-63.
    >> Share

  110. SWIFT BE, Khoja L, Matthews J, Croke J, et al
    Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva.
    Gynecol Oncol. 2024;187:46-50.
    >> Share

    July 2024
  111. DA COSTA AABA, Souza RP, Pandolfi NC, de Souza Castro F, et al
    Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?
    Gynecol Oncol. 2024;189:109-110.
    >> Share

  112. JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al
    Health-related quality of life, sexual function, psychological health, reproductive concerns and fertility outcome in young women treated with fertility-sparing surgery for ovarian tumors - A prospective longitudinal multicentre study.
    Gynecol Oncol. 2024;189:101-108.
    >> Share

  113. ZANNONI GF, Santoro A, Arciuolo D, Travaglino A, et al
    Endometrial cancer and 2023 FIGO staging system: Not too soon, but maybe too much?
    Gynecol Oncol. 2024;189:98-100.
    >> Share

  114. GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al
    Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
    Gynecol Oncol. 2024;189:90-97.
    >> Share

  115. SULLIVAN MW, Kanbergs AN, Growdon WB
    Letter to the Editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review" recently reported from Nahshon et al. (Gynecol Oncol., 188;140-146;2024).
    Gynecol Oncol. 2024;189:88-89.
    >> Share

  116. HUEPENBECKER SP, Soliman PT, Meyer LA, Iniesta MD, et al
    Perioperative outcomes in gynecologic pelvic exenteration before and after implementation of an enhanced recovery after surgery program.
    Gynecol Oncol. 2024;189:80-87.
    >> Share

  117. FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al
    ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2024;189:75-79.
    >> Share

  118. LEE YW, Wang V, Wang MJ, Kim KH, et al
    The effects of Asian American Pacific Islander (AAPI) data inequities in gynecologic oncology.
    Gynecol Oncol. 2024;189:64-67.
    >> Share

  119. KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al
    Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
    Gynecol Oncol. 2024;189:68-74.
    >> Share

  120. CABRERA S, Bebia V, Lopez-Gil C, Luzarraga-Aznar A, et al
    Molecular classification improves preoperative risk assessment of endometrial cancer.
    Gynecol Oncol. 2024;189:56-63.
    >> Share

  121. BERGSTEIN A, Huang Y, Hershman DL, Xu X, et al
    Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis.
    Gynecol Oncol. 2024;189:49-55.
    >> Share

  122. SENGUTTUVAN RN, Lugo-Santiago N, Nakamura B, Song M, et al
    Uterine cancer restaging according to the updated 2023 FIGO Guidelines does not uniformly affect prognosis: An institutional retrospective cohort study.
    Gynecol Oncol. 2024;189:41-48.
    >> Share

  123. POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al
    Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.
    Gynecol Oncol. 2024;189:37-40.
    >> Share

  124. ANDRES S, Finch L, Iasonos A, Zhou Q, et al
    Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
    Gynecol Oncol. 2024;189:30-36.
    >> Share

  125. MAHONEY DE, Mukherjee R, Thompson J
    Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program.
    Gynecol Oncol. 2024;189:24-29.
    >> Share

  126. MCNAMARA B, Greenman M, Bellone S, Santin LA, et al
    Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
    Gynecol Oncol. 2024;189:16-23.
    >> Share

  127. ARO K, Pasanen A, Butzow R, Loukovaara M, et al
    The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.
    Gynecol Oncol. 2024;189:9-15.
    >> Share

  128. GRAHAM O, Rodriguez J, Abbott R, Lomonosova E, et al
    A toolkit for a modern gynecologic oncology tissue bank.
    Gynecol Oncol. 2024;189:1-8.
    >> Share

  129. EZENDAM NPM, de Rooij BH, Creutzberg CL, Kruitwagen RFPM, et al
    Effect of reduced follow-up care on patient satisfaction with care among patients with endometrial cancer: The ENSURE randomized controlled trial.
    Gynecol Oncol. 2024;188:169-183.
    >> Share

  130. KUMAR PP, Smith D, Key J, Dong H, et al
    Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.
    Gynecol Oncol. 2024;188:162-168.
    >> Share

  131. SHALOWITZ DI, Rajczi A
    Refining research on access to gynecologic cancer care: The DIMeS framework.
    Gynecol Oncol. 2024;188:158-161.
    >> Share

  132. CROWLEY F, Broderick S, Francis JH, O'Cearbhaill RE, et al
    Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.
    Gynecol Oncol. 2024;188:147-157.
    >> Share

  133. NAHSHON C, Leitao MM Jr, Lavie O, Schmidt M, et al
    Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review.
    Gynecol Oncol. 2024;188:140-146.
    >> Share

  134. STEWART KT, Jafari H, Pattillo J, Santos J, et al
    Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery.
    Gynecol Oncol. 2024;188:131-139.
    >> Share

  135. RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al
    The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma.
    Gynecol Oncol. 2024;186:110-116.
    >> Share

    June 2024
  136. FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al
    Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
    Gynecol Oncol. 2024;188:97-102.
    >> Share

  137. MEADE CE, Sinnott JA, Backes FJ, Cosgrove CM, et al
    Associations between race and ethnicity and treatment setting among gynecologic cancer patients.
    Gynecol Oncol. 2024;188:111-119.
    >> Share

  138. MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al
    NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
    Gynecol Oncol. 2024;188:103-110.
    >> Share

  139. KA K, Cordoba A, Cagetti LV, Schiappa R, et al
    Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group.
    Gynecol Oncol. 2024;188:90-96.
    >> Share

  140. KOCIAN R, Kohler C, Bajsova S, Jarkovsky J, et al
    Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer.
    Gynecol Oncol. 2024;188:83-89.
    >> Share

  141. MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al
    Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
    Gynecol Oncol. 2024;188:52-57.
    >> Share

  142. KOH B, Ryu JY, Noh JJ, Hwang JR, et al
    Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
    Gynecol Oncol. 2024;188:60-70.
    >> Share

  143. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Corrigendum to "Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study" [Gynecologic Oncology 164/1(2022) 120-128].
    Gynecol Oncol. 2024;188:58-59.
    >> Share

  144. BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al
    The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.
    Gynecol Oncol. 2024;188:44-51.
    >> Share

  145. GARZON S, Calio A, Ferrari FA, Iannicello CQ, et al
    Uterine perivascular epithelioid cell tumors (PEComa) and the accuracy of proposed classification systems in predicting the malignant versus non-malignant behavior.
    Gynecol Oncol. 2024;188:35-43.
    >> Share

  146. CHEN H, Chen Y, Zheng A, Tan X, et al
    Is pharmacologic venous Thromboprophylaxis necessary for patients undergoing minimally invasive surgery for endometrial Cancer? A systematic review and Meta-analysis.
    Gynecol Oncol. 2024;188:27-34.
    >> Share

  147. WALKER CA, Edwards C, McIntire D, Makepeace L, et al
    Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer.
    Gynecol Oncol. 2024;188:22-26.
    >> Share

  148. PATEL KB, Escamilla V, Wolfe L, Morris T, et al
    Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? - A geospatial analysis.
    Gynecol Oncol. 2024;188:8-12.
    >> Share

  149. FLANIGAN MR, Bell SG, Donovan HS, Zhao J, et al
    Variables impacting prolonged post-anesthesia care unit length of stay in gynecologic cancer patients in the era of same day minimally invasive hysterectomy.
    Gynecol Oncol. 2024;186:211-215.
    >> Share

  150. BORHO L, Bao R, Elishaev E, Dinkins KD, et al
    Association of allostatic load with overall survival in epithelial ovarian cancer.
    Gynecol Oncol. 2024;186:204-210.
    >> Share

  151. CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
    Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.
    Gynecol Oncol. 2024;187:249-252.
    >> Share

  152. MAKKER V, Perez-Fidalgo JA, Valabrega G, Hamilton E, et al
    Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
    Gynecol Oncol. 2024 Jun 3:S0090-8258(24)00234.
    >> Share

  153. AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al
    Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
    Gynecol Oncol. 2024;187:241-248.
    >> Share

  154. VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al
    Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Gynecol Oncol. 2024;187:128-138.
    >> Share

  155. O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
    Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
    Gynecol Oncol. 2024;186:199-203.
    >> Share

  156. BERTON D, Pautier P, Lorusso D, Gennigens C, et al
    Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I stud
    Gynecol Oncol. 2024;186:191-198.
    >> Share

  157. CHALIF J, Kistenfeger Q, Fulton J, Morton M, et al
    Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature.
    Gynecol Oncol. 2024;185:165-172.
    >> Share

  158. SCALISE CB, Kincaid K, Thigpen H, Moore J, et al
    A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
    Gynecol Oncol. 2024;185:83-94.
    >> Share

  159. FEINBERG J, Da Cruz Paula A, da Silva EM, Pareja F, et al
    Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements.
    Gynecol Oncol. 2024;185:58-67.
    >> Share

  160. HOHN AK, Forberger M, Alfaraidi M, Gilks CB, et al
    High concordance of molecular subtyping between pre-surgical biopsy and surgical resection specimen (matched-pair analysis) in patients with vulvar squamous cell carcinoma using p16- and p53-immunostaining.
    Gynecol Oncol. 2024;185:17-24.
    >> Share

    May 2024
  161. FRANCO S, Godley LA
    Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.
    Gynecol Oncol. 2024;187:235-240.
    >> Share

  162. LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al
    Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.
    Gynecol Oncol. 2024;187:227-234.
    >> Share

  163. PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al
    Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
    Gynecol Oncol. 2024;187:221-226.
    >> Share

  164. YUAN G, Zhang K, Zheng H, Wu Y, et al
    Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
    Gynecol Oncol. 2024;187:212-220.
    >> Share

  165. CARBALLO EV, Kim KH, Penn CA
    Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients.
    Gynecol Oncol. 2024;187:204-211.
    >> Share

  166. OSAZUWA-PETERS OL, Greiner MA, Kaufman BG, Zambrano Guevara LM, et al
    ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure.
    Gynecol Oncol. 2024;187:184-191.
    >> Share

  167. PERSSON J, Luhrs O, Geppert B, Ekdahl L, et al
    A prospective study evaluating an optimized sentinel node algorithm in early stage cervical cancer: The PROSACC-study.
    Gynecol Oncol. 2024;187:178-183.
    >> Share

  168. MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al
    Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
    Gynecol Oncol. 2024;187:170-177.
    >> Share

  169. LARAJA A, Connor Y, Poulson MR
    The effect of urban racial residential segregation on ovarian cancer diagnosis, treatment, and survival.
    Gynecol Oncol. 2024;187:163-169.
    >> Share

  170. FERRIS JS, Prest MT, Hur C, Chen L, et al
    Trends in uterine cancer incidence in the United States: The contribution of age, period and cohort effects.
    Gynecol Oncol. 2024;187:151-162.
    >> Share

  171. ZENATRI M, Perennec T, Michon C, Gernier F, et al
    Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
    Gynecol Oncol. 2024;187:139-144.
    >> Share

  172. HUNSBERGER KS, Treiman S, Monk BJ, Tewari KS, et al
    A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
    Gynecol Oncol. 2024;187:120-127.
    >> Share

  173. LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al
    A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
    Gynecol Oncol. 2024;187:105-112.
    >> Share

  174. ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al
    Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer.
    Gynecol Oncol. 2024;187:98-104.
    >> Share

  175. PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al
    Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Gynecol Oncol. 2024;187:92-97.
    >> Share

  176. KIM JH, Han KH, Park EY, Kim ET, et al
    Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;187:85-91.
    >> Share

  177. FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al
    Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2024;187:80-84.
    >> Share

  178. LIANG S, Ge H, Zhou S, Tang J, et al
    Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST.
    Gynecol Oncol. 2024;187:64-73.
    >> Share

  179. CHIBA Y, Kojima Y, Yazaki S, Yoshida H, et al
    Trop-2 expression and the tumor immune microenvironment in cervical cancer.
    Gynecol Oncol. 2024;187:51-57.
    >> Share

  180. GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al
    Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
    Gynecol Oncol. 2024;186:182-190.
    >> Share

  181. MATSUO K, Chen L, Klar M, Lee MW, et al
    Prognostic performance of the 2023 FIGO staging schema for endometrial cancer.
    Gynecol Oncol. 2024;187:37-45.
    >> Share

  182. MITRIC C, Sayyid RK, Fleshner NE, Look Hong NJ, et al
    Hysterectomy versus chemotherapy for low-risk non-metastatic gestational trophoblastic neoplasia (GTN): A cost-effectiveness analysis.
    Gynecol Oncol. 2024;187:30-36.
    >> Share

  183. PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al
    Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk.
    Gynecol Oncol. 2024;187:21-29.
    >> Share

  184. DEMIRKIRAN C, Greenman M, Bellone S, McNamara B, et al
    Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
    Gynecol Oncol. 2024;187:12-20.
    >> Share

  185. RING KL, Duska LR
    How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations.
    Gynecol Oncol. 2024;184:8-15.
    >> Share

  186. MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al
    Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
    Gynecol Oncol. 2024;184:16-23.
    >> Share

    April 2024
  187. HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al
    Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors.
    Gynecol Oncol. 2024;186:176-181.
    >> Share

  188. JIANG Z, Zhu M, Zhang L, Cui H, et al
    Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer.
    Gynecol Oncol. 2024;187:1-11.
    >> Share

  189. HOFFMAN M, Dunsmore V, Cliby W, Chi D, et al
    Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education.
    Gynecol Oncol. 2024;184:254-258.
    >> Share

  190. SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al
    "Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
    Gynecol Oncol. 2024;186:170-175.
    >> Share

  191. CHALIF J, Chambers LM, Yao M, Kuznicki M, et al
    Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
    Gynecol Oncol. 2024;186:161-169.
    >> Share

  192. PENG H, Jiang J, Li L, Hao Z, et al
    Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment.
    Gynecol Oncol. 2024;186:154-160.
    >> Share

  193. ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al
    Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
    Gynecol Oncol. 2024;186:144-153.
    >> Share

  194. PATEL JM, Hermann CE, Growdon WB, Aviki E, et al
    ChatGPT accurately performs genetic counseling for gynecologic cancers.
    Gynecol Oncol. 2024;183:115-119.
    >> Share

  195. WANG CC, Grubbs A, Foley OW, Bharadwa S, et al
    The activity advantage: Objective measurement of preoperative activity is associated with postoperative recovery and outcomes in patients undergoing surgery with gynecologic oncologists.
    Gynecol Oncol. 2024;186:137-143.
    >> Share

  196. ZHAO Z, Wang J, Kong W, Fang Z, et al
    Intermittent energy restriction inhibits tumor growth and enhances paclitaxel response in a transgenic mouse model of endometrial cancer.
    Gynecol Oncol. 2024;186:126-136.
    >> Share

  197. NELSON AT, Harris AK, Watson D, Kamihara J, et al
    Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries.
    Gynecol Oncol. 2024;186:117-125.
    >> Share

  198. EHMANN S, Lam C, Zhou Q, Iasonos A, et al
    Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;186:104-109.
    >> Share

  199. ESPINOSA I, D'Angelo E, Prat J
    Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
    Gynecol Oncol. 2024;186:94-103.
    >> Share

  200. MATSUO K, Huang Y, Matsuzaki S, Vallejo A, et al
    Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment.
    Gynecol Oncol. 2024;186:85-93.
    >> Share

  201. GITTO SB, Ihewulezi CJN, Powell DJ Jr
    Adoptive T cell therapy for ovarian cancer.
    Gynecol Oncol. 2024;186:77-84.
    >> Share

  202. DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
    Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2024;186:69-76.
    >> Share

  203. GIEN LT, Enserro DM, Block MS, Waggoner S, et al
    Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
    Gynecol Oncol. 2024;186:61-68.
    >> Share

  204. SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
    Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
    Gynecol Oncol. 2024;186:53-60.
    >> Share

  205. KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al
    Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
    Gynecol Oncol. 2024;183:103-114.
    >> Share

  206. HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al
    High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:42-52.
    >> Share

  207. VESZTERGOM D, Teglas G, Bahrehmand K, Torok A, et al
    Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study.
    Gynecol Oncol. 2024;186:35-41.
    >> Share


  208. Introduction to SGO VSI.
    Gynecol Oncol. 2024;183:A7.
    >> Share

  209. RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
    Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
    Gynecol Oncol. 2024;183:R1.
    >> Share

    March 2024
  210. MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al
    TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:26-34.
    >> Share

  211. SHEN X, Wang J, Deng B, Chen S, et al
    High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
    Gynecol Oncol. 2024;183:93-102.
    >> Share

  212. SALINARO JR, Rossi EC, Penvose KN, Zhang Y, et al
    Delayed publication of clinical trials in gynecologic oncology.
    Gynecol Oncol. 2024;183:74-77.
    >> Share

  213. HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
    Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
    Gynecol Oncol. 2024;186:9-16.
    >> Share

  214. DESRAVINES N, Hazimeh D, Desjardins MR, Wethington SL, et al
    Healthcare utilization in women diagnosed with endometrial cancer: A survey-based study.
    Gynecol Oncol. 2024;186:1-8.
    >> Share

  215. WILLIAMS-BROWN MY, Summey RM, Newtson A, Burke W, et al
    System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review.
    Gynecol Oncol. 2024;183:85-92.
    >> Share

  216. RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
    Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
    Gynecol Oncol. 2024;183:78-84.
    >> Share

  217. KIM NK, Choi CH, Seong SJ, Lee JM, et al
    Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
    Gynecol Oncol. 2024;183:68-73.
    >> Share

  218. PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al
    Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
    Gynecol Oncol. 2024;183:61-67.
    >> Share

  219. LIANG MI, Dholakia JD, Lee GM, Wang L, et al
    Dedicated financial hardship screening adds value to routine distress screening among gynecologic cancer patients.
    Gynecol Oncol. 2024;183:53-60.
    >> Share

  220. AHSAN MD, Webster EM, Wolfe IA, McGonigle R, et al
    Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic.
    Gynecol Oncol. 2024;183:47-52.
    >> Share

  221. HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
    Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study.
    Gynecol Oncol. 2024;183:39-46.
    >> Share

  222. LEVINE BJ
    Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics.
    Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
    >> Share

  223. ROSS DH, Gomez K, Harmon G, Mysz ML, et al
    Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer.
    Gynecol Oncol. 2024;183:33-38.
    >> Share

  224. CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al
    Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors.
    Gynecol Oncol. 2024;183:15-24.
    >> Share

  225. BYRNE M, Sia TY, Fong C, Khurram A, et al
    Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
    Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
    >> Share

  226. GASS P, Thiel FC, Haberle L, Ackermann S, et al
    Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
    Gynecol Oncol. 2024;183:25-32.
    >> Share

  227. BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al
    Corrigendum to "Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80].
    Gynecol Oncol. 2024;183:7-8.
    >> Share

  228. GLASER GE, Maddy B, Kumar A, Ishitani K, et al
    Impact of pharmacogenomic profiles on post-surgical pain following laparotomy for gynecologic pathology.
    Gynecol Oncol. 2024;183:9-14.
    >> Share

  229. PANDYA D, Tomita S, Rhenals MP, Swierczek S, et al
    Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue.
    Gynecol Oncol. 2024;185:194-201.
    >> Share

  230. GAFFNEY D, Matias-Guiu X, Mutch D, Scambia G, et al
    2023 FIGO staging system for endometrial cancer: The evolution of the revolution.
    Gynecol Oncol. 2024;184:245-253.
    >> Share

  231. RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al
    Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;185:186-193.
    >> Share

  232. NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA
    Real world challenges and disparities in the systemic treatment of ovarian cancer.
    Gynecol Oncol. 2024;185:180-185.
    >> Share

  233. OLAWAIYE AB
    2023 FIGO staging for endometrial cancer, a look at both sides of the coin.
    Gynecol Oncol. 2024;184:243-244.
    >> Share

  234. EJAREDAR M, Ruzycki SM, Glazer TS, Trudeau P, et al
    Implementation of a surgical site infection prevention bundle in gynecologic oncology patients: An enhanced recovery after surgery initiative.
    Gynecol Oncol. 2024;185:173-179.
    >> Share

  235. GLASER GE, Dowdy SC
    Sentinel lymph node biopsy in high-risk endometrial cancer: The denouement.
    Gynecol Oncol. 2024;182:A1-A2.
    >> Share

  236. CHEN W, Xie J, Gao C, Zhang C, et al
    Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
    Gynecol Oncol. 2024;182:108-114.
    >> Share

    February 2024
  237. CAO B, Li Y, Liu Y, Chen X, et al
    A multi-center study to predict the risk of intraoperative hypothermia in gynecological surgery patients using preoperative variables.
    Gynecol Oncol. 2024;185:156-164.
    >> Share

  238. CHEN Y, Yang J, Wan Y, Li Q, et al
    DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial.
    Gynecol Oncol. 2024;185:148-155.
    >> Share

  239. COSTALES AB, Crane EK, Chambers L, Yao M, et al
    Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
    Gynecol Oncol. 2024;185:143-147.
    >> Share

  240. SALMAN L, Covens A, Vicus D, Podolsky S, et al
    The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study.
    Gynecol Oncol. 2024;185:138-142.
    >> Share

  241. RONCOLATO F, King MT, O'Connell RL, Lee YC, et al
    Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
    Gynecol Oncol. 2024;185:128-137.
    >> Share

  242. AGUSTI N, Kanbergs A, Nitecki R
    Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.
    Gynecol Oncol. 2024;185:121-127.
    >> Share

  243. PENFOUND S, Lukey A, Hodgson J, Hopman WM, et al
    Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database.
    Gynecol Oncol. 2024;185:116-120.
    >> Share

  244. KRISTENSEN AK, Frandsen CLB, Nohr B, Viuff JH, et al
    Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women.
    Gynecol Oncol. 2024;185:108-115.
    >> Share

  245. HICKS ML, Hicks MM, Mathews RP, Khabele D, et al
    Racial disparities in endometrial cancer: Where are we after 26 years?
    Gynecol Oncol. 2024;184:236-242.
    >> Share

  246. NICA A, Benseler A, Parbhakar A, Fortin LT, et al
    Robotic versus vaginal radical trachelectomy for reproductive-aged patients with early-stage cervical carcinoma: A multi-center cohort study.
    Gynecol Oncol. 2024;185:95-100.
    >> Share

  247. SUIDAN RS, Sun CC, Schneider AK, Lu KH, et al
    Determination of quality of life-related health utilities for surgical complications in ovarian cancer.
    Gynecol Oncol. 2024;185:101-107.
    >> Share

  248. GARRETT AA, Bai S, Cascio S, Gupta N, et al
    EGFL6 promotes endometrial cancer cell migration and proliferation.
    Gynecol Oncol. 2024;185:75-82.
    >> Share

  249. SARIPALLI AL, Ross DH, Murphy E, Gomez K, et al
    Prevalence of trauma history and symptoms in patients who have received vaginal brachytherapy as part of their endometrial cancer treatment.
    Gynecol Oncol. 2024;185:68-74.
    >> Share

  250. KADOCH E, Brezinov Y, Levin G, Racovitan F, et al
    The impact of body mass index on robotic surgery outcomes in endometrial cancer.
    Gynecol Oncol. 2024;185:51-57.
    >> Share

  251. ROOF KA, Wichmann HK, Carlton LJ, Nguyen ML, et al
    Factors associated with loss to follow up after abnormal cervical cancer screening in pregnancy.
    Gynecol Oncol. 2024;185:46-50.
    >> Share

  252. KNISELY A, Iniesta MD, Batman S, Meyer LA, et al
    Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center.
    Gynecol Oncol. 2024 Feb 16:S0090-8258(24)00065.
    >> Share

  253. HICKS ML, Matthews RP, Clare CA, Lawson YR, et al
    The impact of Black founding fathers on the specialty of gynecologic oncology.
    Gynecol Oncol. 2024;185:42-45.
    >> Share

  254. DISIPIO T, Hartel G, Butow P, Webb PM, et al
    Impact of disease recurrence on the supportive care needs of patients with ovarian cancer and their caregivers.
    Gynecol Oncol. 2024;185:33-41.
    >> Share

  255. ABADA E, Kim S, Jang H, Kheil M, et al
    Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions.
    Gynecol Oncol. 2024;185:25-32.
    >> Share

  256. CHANG C, Cheng YY, Kamlapurkar S, White S, et al
    GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15.
    Gynecol Oncol. 2024;185:8-16.
    >> Share

  257. MADARIAGA A, Cole H, Pittman T, Grant RC, et al
    High grade adverse event reporting and enrolment in gynecologic oncology clinical trials.
    Gynecol Oncol. 2024;185:1-7.
    >> Share

  258. KUCERA CW, Chappell NP, Tian C, Richardson MT, et al
    Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors.
    Gynecol Oncol. 2024;184:224-235.
    >> Share

  259. DINICU AI, Dioun S, Wang Y, Huang Y, et al
    Survival rates in Hispanic/Latinx subpopulations with cervical cancer associated with disparities in guideline-concordant care.
    Gynecol Oncol. 2024;184:214-223.
    >> Share

  260. WESSMAN S, Nister M, Kokaraki G, Pal N, et al
    A comprehensive population-based study of malignant ovarian tumors, including histologic and immunohistochemical review, in children and adolescents 0-19 years old in Sweden between 1970 and 2014.
    Gynecol Oncol. 2024;184:206-213.
    >> Share

  261. MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
    Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
    Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
    >> Share

  262. BJORNHOLT SM, Mogensen O, Bouchelouche K, Sponholtz SE, et al
    Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo study.
    Gynecol Oncol. 2024;182:179-187.
    >> Share

  263. HAN L, Chen Y, Zheng A, Tan X, et al
    Prognostic value of three-tiered scoring system for lymph-vascular space invasion in endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;184:198-205.
    >> Share

  264. SOMASEGAR S, Reddy RA, Chow S, Dorigo O, et al
    Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis.
    Gynecol Oncol. 2024;184:190-197.
    >> Share

  265. STEVENTON L, Nicum S, Man K, Chaichana U, et al
    A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancers.
    Gynecol Oncol. 2024;184:178-189.
    >> Share

  266. LEVINE MD, Wagner VM, Riedinger CJ, Khadraoui W, et al
    Authentic leadership in action: Experience gained from a gynecologic oncology fellowship leadership curriculum.
    Gynecol Oncol. 2024;182:176-178.
    >> Share

  267. POTHURI B, Han S, Chase DM, Heitz F, et al
    Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
    Gynecol Oncol. 2024;184:168-177.
    >> Share

  268. SMITH AJB, Gleason EG, Andriani L, Heintz J, et al
    Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities?
    Gynecol Oncol. 2024;184:160-167.
    >> Share

  269. ROSATO R, Ferrero A, Mosconi P, Ciccone G, et al
    Impact of different follow-up regimens on health-related quality of life and costs in endometrial cancer patients: Results from the TOTEM randomized trial.
    Gynecol Oncol. 2024;184:150-159.
    >> Share

  270. LEITAO MM JR
    2023 changes to FIGO endometrial cancer staging: Counterpoint.
    Gynecol Oncol. 2024;184:146-149.
    >> Share

  271. TELLES R, Zimmerman MB, Thaker PH, Slavich GM, et al
    Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients.
    Gynecol Oncol. 2024;184:139-145.
    >> Share

  272. YOON H, Suh DH, Kim K, No JH, et al
    Evaluation of prognostic potential of beta-catenin and L1CAM expression according to endometrial cancer risk group.
    Gynecol Oncol. 2024;184:132-138.
    >> Share

  273. HARI A, Chang J, Villanueva C, Ziogas A, et al
    Short-term survival analysis of a risk-adjusted model for ovarian cancer care.
    Gynecol Oncol. 2024;184:123-131.
    >> Share

  274. AROCHE GUTIERREZ LL, McIntire DD, Lea J, LoCoco S, et al
    Social determinants of health in uterine carcinosarcoma.
    Gynecol Oncol. 2024;184:117-122.
    >> Share

  275. APPLEBAUM AJ
    The importance of family-focused care in the setting of advanced gynecological cancers.
    Gynecol Oncol. 2024;181:A1-A2.
    >> Share

  276. PELTECU G
    Eugen Bogdan Aburel, a pioneer of fertility sparing surgery.
    Gynecol Oncol. 2024;181:40-45.
    >> Share

  277. VASTA FM, Cormio G, Cassani C, Bergamini A, et al
    Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
    Gynecol Oncol. 2024;181:28-32.
    >> Share

  278. TAYLOR DD, Gercel-Taylor C, Parker LP
    Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
    Gynecol Oncol. 2024;181:186.
    >> Share

    January 2024
  279. DORISMOND VG, Saraiya M, Gopalani SV, Soman A, et al
    Variation in cervical cancer screening test utilization and results in a United States-based program.
    Gynecol Oncol. 2024;184:96-102.
    >> Share

  280. BEFANO B, Wentzensen N, Lorey T, Poitras N, et al
    Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
    Gynecol Oncol. 2024;184:89-95.
    >> Share

  281. LEITE S, Chen YS, Walker A, Riccio K, et al
    Role of sentinel lymph node evaluation during hysterectomy for preoperative pathology diagnosis of endometrial intraepithelial neoplasia in a community hospital setting.
    Gynecol Oncol. 2024;184:83-88.
    >> Share

  282. MCNALLY L, Wu S, Hodges K, Oberley M, et al
    Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets.
    Gynecol Oncol. 2024;184:111-116.
    >> Share

  283. RIEDER SM, Burgess E, Rutledge T, Sussman A, et al
    Critical decisions: A mixed-methods study of decision-making among diverse gynecologic cancer patients considering therapeutic clinical trial enrollment.
    Gynecol Oncol. 2024;184:103-110.
    >> Share

  284. SANTORO A, Angelico G, Inzani F, Arciuolo D, et al
    The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations.
    Gynecol Oncol. 2024;184:57-66.
    >> Share

  285. TUBRIDY EA, Eiva MA, Liu F, Omran DK, et al
    CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
    Gynecol Oncol. 2024;184:74-82.
    >> Share

  286. WEHN AK, Qiu P, Lunceford J, Yarunin A, et al
    Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
    Gynecol Oncol. 2024;184:67-73.
    >> Share

  287. MOFFAT GT, Kong W, MacKay HJ, McGee J, et al
    Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
    Gynecol Oncol. 2024;184:51-56.
    >> Share

  288. WANG CC, Foley OW, Blank SV, Huh WK, et al
    Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists.
    Gynecol Oncol. 2024;184:43-50.
    >> Share

  289. WINKLER SS, Tian C, Casablanca Y, Bateman NW, et al
    Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypes.
    Gynecol Oncol. 2024;184:31-42.
    >> Share

  290. MUSACCHIO L, Palluzzi E, Di Napoli M, Lauria R, et al
    Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
    Gynecol Oncol. 2024;184:24-30.
    >> Share

  291. FADER AN, Ko EM, Pollock BD, Blank SV, et al
    An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care?
    Gynecol Oncol. 2024 Jan 25:S0090-8258(24)00002.
    >> Share

  292. MANNING-GEIST B, Grace MA, Sonoda Y
    Trachelectomy and fertility-sparing procedures for early-stage cervical cancer: A state of the science review.
    Gynecol Oncol. 2024;181:179-182.
    >> Share

  293. BAN D, Housley SN, Matyunina LV, McDonald LD, et al
    A personalized probabilistic approach to ovarian cancer diagnostics.
    Gynecol Oncol. 2024;182:168-175.
    >> Share

  294. YANG Q, Peng X, Nian Z, Yuan S, et al
    UCHL-3 as a potential biomarker of ovarian cancer.
    Gynecol Oncol. 2024;182:156-167.
    >> Share

  295. VILLIGER AS, Zurbriggen S, Imboden S, Solass W, et al
    Reviving peritoneal cytology: Exploring its role in endometrial cancer molecular classification.
    Gynecol Oncol. 2024;182:148-155.
    >> Share

  296. CASANOVA J, Duarte GS, da Costa AG, Catarino A, et al
    Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2024;182:99-107.
    >> Share

  297. WANG CC, Bharadwa S, Domenech I, Barber EL, et al
    In the patient's shoes: The impact of hospital proximity and volume on stage I endometrial cancer care patterns and outcomes.
    Gynecol Oncol. 2024;182:91-98.
    >> Share

  298. WEIGERT M, Cui XL, West-Szymanski D, Yu X, et al
    5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
    Gynecol Oncol. 2024;182:82-90.
    >> Share

  299. LUMISH M, Chui MH, Zhou Q, Iasonos A, et al
    A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
    Gynecol Oncol. 2024;182:75-81.
    >> Share

  300. DIOUN S, Chen L, De Meritens AB, St Clair CM, et al
    Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
    Gynecol Oncol. 2024;182:70-74.
    >> Share

  301. RECIO F, Scalise CB, Loar P, Lumish M, et al
    Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.
    Gynecol Oncol. 2024;182:63-69.
    >> Share

  302. TORTORELLA L, Cappuccio S, Giannarelli D, Nero C, et al
    Distribution and prognostic role of BRCA status in elderly ovarian cancer patients.
    Gynecol Oncol. 2024;182:57-62.
    >> Share

  303. LEVINE MD, Wang H, Sriram B, Khan A, et al
    Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
    Gynecol Oncol. 2024;182:51-56.
    >> Share

  304. KAHN RM, Ma X, Gordhandas S, Yeoshoua E, et al
    Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State.
    Gynecol Oncol. 2024;182:141-147.
    >> Share

  305. LEE SS, Gold HT, Kwon SC, Pothuri B, et al
    Guideline concordant care for patients with locally advanced cervical cancer by disaggregated Asian American and Native Hawaiian/Pacific Islander groups: A National Cancer Database Analysis.
    Gynecol Oncol. 2024;182:132-140.
    >> Share

  306. CRISTEA MC, Stewart D, Synold T, Ruel N, et al
    A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRalpha-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
    Gynecol Oncol. 2024;182:124-131.
    >> Share

  307. CRUTTENDEN J, Balogun OD, Gaffney D, Suneja G, et al
    Destigmatizing gynecologic cancers and prioritizing prospective radiotherapy studies.
    Gynecol Oncol. 2024;182:121-123.
    >> Share

  308. FIFE AJ, Najor AJ, Aspir TB, Haines KE, et al
    Reduced healthcare access contributes to delay of care in endometrial cancer.
    Gynecol Oncol. 2024;182:115-120.
    >> Share

  309. KIM SI, Joung JG, Kim YN, Park J, et al
    Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
    Gynecol Oncol. 2024;182:7-14.
    >> Share

  310. CHOI KH, Lee HC, Kim YS, Park W, et al
    Diagnostic assessments and treatment results of well-differentiated gastric-type adenocarcinoma of the uterine cervix (Adenoma malignum): A multicenter retrospective analysis of KROG 22-03 study.
    Gynecol Oncol. 2024;182:45-50.
    >> Share

  311. KIM HJ, Lee J, Lee KB, Sung K, et al
    Choosing the right adjuvant therapy for stage III-IVA endometrial cancer: A comparative analysis of chemoradiotherapy and chemotherapy.
    Gynecol Oncol. 2024;182:39-44.
    >> Share

  312. PRAISS AM, White C, Iasonos A, Selenica P, et al
    Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
    Gynecol Oncol. 2024;182:32-38.
    >> Share

  313. JOHNSON CR, Liao CI, Tian C, Richardson MT, et al
    Uterine cancer among Asian Americans - Disparities & clinical characteristics.
    Gynecol Oncol. 2024;182:24-31.
    >> Share

  314. XIE H, Li M, Zheng Y
    Associations of metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;182:15-23.
    >> Share

  315. HANNIBAL CG, Kjaer SK, Galanakis M, Hertzum-Larsen R, et al
    History of autoimmune disease and long-term survival of epithelial ovarian cancer: The extreme study.
    Gynecol Oncol. 2024;182:1-6.
    >> Share

  316. GRESSEL GM, Frey MK, Norquist B, Senter L, et al
    Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2024;181:170-178.
    >> Share

  317. SZAMRETA EA, Monberg MJ, Desai KD, Li Y, et al
    Prognosis and conditional survival among women with newly diagnosed ovarian cancer.
    Gynecol Oncol. 2024;180:170-177.
    >> Share

  318. FRIEDMAN CF, D'Souza A, Bello Roufai D, Tinker AV, et al
    Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
    Gynecol Oncol. 2024;181:162-169.
    >> Share

  319. ALSOMAIRI A, Himayda S, Altelmesani A, Lee YJ, et al
    Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
    Gynecol Oncol. 2024;181:155-161.
    >> Share

  320. GLASER G, Weroha J
    What's in your "lunchbox"? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancer.
    Gynecol Oncol. 2024;180:A1-A2.
    >> Share

  321. GORDINIER ME, Schau GF, Pollock SB, Shields LBE, et al
    Genomic characterization of vulvar squamous cell carcinoma reveals differential gene expression based on clinical outcome.
    Gynecol Oncol. 2024;180:111-117.
    >> Share

    December 2023
  322. TJIOE KC, Miranda-Galvis M, Johnson MS, Agrawal G, et al
    The interaction between social determinants of health and cervical cancer survival: A systematic review.
    Gynecol Oncol. 2023;181:141-154.
    >> Share

  323. HAGOPIAN GS, Bapat AC, Dottino PR, Lieber M, et al
    The impact of nativity on uterine cancer survival in the public hospital system of Queens, New York.
    Gynecol Oncol. 2023;181:133-140.
    >> Share

  324. WU MF, Cheng XY, Wang DY, Lai YT, et al
    Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial.
    Gynecol Oncol. 2023;181:125-132.
    >> Share

  325. ALTMANN J, Schmitt W, Bashian N, Sehouli J, et al
    A dramatic response to checkpoint inhibitor in a woman with small cell carcinoma of the hypercalcemic type of the ovary.
    Gynecol Oncol. 2023;181:99-101.
    >> Share

  326. PENVOSE KN, Reed SD, Sepulveda JMG, Mastylak A, et al
    Development and testing of patient-centered education about hormone replacement therapy for women at high genetic risk of breast and ovarian cancer.
    Gynecol Oncol. 2023;181:91-98.
    >> Share

  327. REDDY M, Tian C, Liao CI, Winkler S, et al
    Exploring U.S. Hispanic origin groups diagnosed with uterine cancer - Are there disparities?
    Gynecol Oncol. 2023;181:118-124.
    >> Share

  328. HALLE MK, Bozickovic O, Forsse D, Wagner-Larsen KS, et al
    Clinicopathological and radiological stratification within FIGO 2018 stages improves risk-prediction in cervical cancer.
    Gynecol Oncol. 2023;181:110-117.
    >> Share

  329. DE SOUZA NOBREGA F, Alvarenga-Bezerra V, Barbosa GB, Salim RC, et al
    Vaginal hysterectomy for the treatment of low-risk endometrial cancer: Surgical technique, costs, and perioperative and oncologic results.
    Gynecol Oncol. 2023;181:76-82.
    >> Share

  330. RIVES TA, Orellana TJ, Mumford BS, Sukumvanich P, et al
    The role of obesity in treatment planning for early-stage cervical cancer.
    Gynecol Oncol. 2023;181:60-67.
    >> Share

  331. CHAN JK, Tian C, Kesterson JP, Lin KY, et al
    Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
    Gynecol Oncol. 2023;181:54-59.
    >> Share

  332. NISHIO S, Murotani K, Yamagami W, Suzuki S, et al
    Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis.
    Gynecol Oncol. 2023;181:46-53.
    >> Share

  333. KIM JH, Kim SI, Park EY, Kim ET, et al
    Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2023;181:33-39.
    >> Share

  334. URBUTE A, Frederiksen K, Thomsen LT, Kesmodel US, et al
    Overweight and obesity as risk factors for cervical cancer and detection of precancers among screened women: A nationwide, population-based cohort study.
    Gynecol Oncol. 2023;181:20-27.
    >> Share

  335. BENOIT L, Boudebza A, Bentivegna E, Nguyen-Xuan HT, et al
    What is the most pertinent definition of malnutrition in epithelial ovarian cancer to assess morbidity and mortality?
    Gynecol Oncol. 2023;181:12-19.
    >> Share

  336. MAYER CM, O'Connor RM, Do AT, Cerda VR, et al
    Association between adherence to posttreatment National Comprehensive Cancer Network (NCCN) surveillance guidelines and detection of recurrent uterine cancer.
    Gynecol Oncol. 2023;181:8-11.
    >> Share

  337. RICHARDSON MT, Barry D, Steinberg JR, Thirunavu V, et al
    Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials.
    Gynecol Oncol. 2023;181:1-7.
    >> Share

  338. XU X, Kong X, Liu T, Zhou L, et al
    Corrigendum to "Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway" [Gynecol Oncol. 2019 Jul;154(1):207-217. doi: 10.1016/j.ygyno.2019.04.005. Epub 2019 Apr 9].
    Gynecol Oncol. 2023;180:168-169.
    >> Share

  339. ARMBRUSTER SD, Brow K, Locklear T, Frazier M, et al
    Mixed-method approach to informing a lifestyle intervention to improve the survivorship of patients with endometrial cancer.
    Gynecol Oncol. 2023;180:160-167.
    >> Share

  340. PARKER VL, Winter MC, Tidy JA, Palmer JE, et al
    PREDICT-GTN 2: Two-factor streamlined models match FIGO performance in gestational trophoblastic neoplasia.
    Gynecol Oncol. 2023;180:152-159.
    >> Share

  341. VAHTERISTO M, Leinonen MK, Sarkeala T, Anttila A, et al
    Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial.
    Gynecol Oncol. 2023;180:146-151.
    >> Share

  342. BERNARD L, How JA, Patel S, Yates MS, et al
    Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab.
    Gynecol Oncol. 2023;180:139-145.
    >> Share

  343. DARKO N, Millet N, Usman A, Teece L, et al
    Exploring the perspectives of underrepresented voices: Perceptions and experiences of uterine cancer for black African, Caribbean, black British, and mixed-black women in the UK to develop strategies for early symptom presentation.
    Gynecol Oncol. 2023;180:132-138.
    >> Share

  344. CHAUHAN S, Langstraat CL, Fought AJ, McGree ME, et al
    Relationship between frailty and nutrition: Refining predictors of mortality after primary cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2023;180:126-131.
    >> Share

  345. XU X, Chen L, Nunez-Smith M, Clark M, et al
    Black-White differences in uterine cancer symptomatology and stage at diagnosis.
    Gynecol Oncol. 2023;180:118-125.
    >> Share

  346. YIN X, Zhao S, Zhang M, Xing J, et al
    m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer.
    Gynecol Oncol. 2023;180:99-110.
    >> Share

  347. VANBRABAND J, Van Damme N, Silversmit G, De Geyndt A, et al
    Practice patterns, time trends and quality of care of uterine cancer in Belgium: An analysis of the EFFECT database.
    Gynecol Oncol. 2023;180:70-78.
    >> Share

  348. KOSKELA H, Li Y, Joutsiniemi T, Muranen T, et al
    HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
    Gynecol Oncol. 2023;180:91-98.
    >> Share

  349. CHASE DM, Annavarapu S, Tseng WY, Shi J, et al
    Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
    Gynecol Oncol. 2023;180:79-85.
    >> Share

  350. BARLIN JN, Mahar B, Ata A, Cormier B, et al
    Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial car
    Gynecol Oncol. 2023;180:63-69.
    >> Share

  351. HSIEH K, Bloom JR, Dickstein DR, Hsieh C, et al
    Dose and fractionation regimen for brachytherapy boost in cervical cancer in the US.
    Gynecol Oncol. 2023;180:55-62.
    >> Share

  352. RAI R, Lightfoot S, Benbrook DM
    Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts.
    Gynecol Oncol. 2023;180:44-54.
    >> Share

  353. KITSON SJ, Crosbie EJ
    Optimising endometrial cancer survivorship through lifestyle change.
    Gynecol Oncol. 2023;179:A1-A2.
    >> Share

  354. LONG E, Macdonald MC, Parker VL, Lyon R, et al
    Factors associated with failed 'test of cure' in the NHS Cervical Screening Programme: A retrospective cohort study.
    Gynecol Oncol. 2023;179:158-163.
    >> Share

  355. SCHUURMAN MS, Veldmate G, Ebisch RMF, de Hullu JA, et al
    Vulvar squamous cell carcinoma in women 80 years and older: Treatment, survival and impact of comorbidities.
    Gynecol Oncol. 2023;179:91-96.
    >> Share

  356. KAHN RM, Selenica P, Boerner T, Roche KL, et al
    Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
    Gynecol Oncol. 2023;180:35-43.
    >> Share

  357. SAMMOURI J, Venkatesan AM, Lin LL, Jhingran A, et al
    Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement.
    Gynecol Oncol. 2023;180:24-34.
    >> Share

  358. SUZUKI Y, Chen L, Ferris JS, St Clair CM, et al
    Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer.
    Gynecol Oncol. 2023;180:14-23.
    >> Share

    November 2023
  359. RYDZINSKI M, Bijok M, Michalski W, Kowalczyk A, et al
    Image-guided high-dose-rate brachytherapy as the method of choice in medically inoperable early-stage endometrial cancer patients.
    Gynecol Oncol. 2023;180:6-13.
    >> Share

  360. NASIOUDIS D, Gysler S, Latif N, Cory L, et al
    Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
    Gynecol Oncol. 2023;180:1-5.
    >> Share

  361. DAGHER C, Manning-Geist B, Ellenson LH, Weigelt B, et al
    Molecular subtyping in endometrial cancer: A promising strategy to guide fertility preservation.
    Gynecol Oncol. 2023;179:180-187.
    >> Share

  362. PRAISS AM, Hirani R, Zhou Q, Iasonos A, et al
    Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2023;179:169-179.
    >> Share

  363. HERMANN CE, Patel JM, Boyd L, Growdon WB, et al
    Let's chat about cervical cancer: Assessing the accuracy of ChatGPT responses to cervical cancer questions.
    Gynecol Oncol. 2023;179:164-168.
    >> Share

  364. SASSE SA, Lee SS, Rajeev P, Sharma SR, et al
    Concurrent uterine surgery and uptake of hormone therapy in patients undergoing bilateral salpingo-oophorectomy for risk-reducing or therapeutic indications.
    Gynecol Oncol. 2023;179:131-137.
    >> Share

  365. ARYASOMAYAJULA C, Stewart C, Eakin C, Reiser H, et al
    Impact of limiting reproductive rights of pregnant individuals with cancer in the United States.
    Gynecol Oncol. 2023 Nov 17:S0090-8258(23)01530.
    >> Share

  366. LIM YH, Dagher C, Abu-Rustum NR, Mueller JJ, et al
    Oncologic outcomes of robot-assisted laparoscopy versus conventional laparoscopy for the treatment of apparent early-stage endometrioid adenocarcinoma of the uterus.
    Gynecol Oncol. 2023;179:152-157.
    >> Share

  367. AGUSTI N, Vidal-Sicart S, Paredes P, Celada-Castro C, et al
    Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a further step towards lymphadenectomy replacement.
    Gynecol Oncol. 2023;179:145-151.
    >> Share

  368. COTANGCO K, Pineda E, Hingarh V, Nyakudarika NC, et al
    Integrating social care into gynecologic oncology: Identifying and addressing patient's social needs.
    Gynecol Oncol. 2023;179:138-144.
    >> Share

  369. DILLEY J, Gentry-Maharaj A, Ryan A, Burnell M, et al
    Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Gynecol Oncol. 2023;179:123-130.
    >> Share

  370. GIRDA E, Randall LM, Chino F, Monk BJ, et al
    Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement.
    Gynecol Oncol. 2023;179:115-122.
    >> Share

  371. KIM J, Lim J, Lee SW, Park JY, et al
    Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2023;179:106-114.
    >> Share

  372. BAUMANN KE, Siamakpour-Reihani S, Dottino J, Dai Y, et al
    High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.
    Gynecol Oncol. 2023;179:97-105.
    >> Share

  373. BESHAR I, Moon AS, Darji H, Liu C, et al
    Aberrant nuclear beta-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study.
    Gynecol Oncol. 2023;179:85-90.
    >> Share

  374. KUMAR R, Sherwani Z, Lopez M, Vergalasova I, et al
    Disparities in brachytherapy utilization in cervical cancer in the United States: A comprehensive literature review.
    Gynecol Oncol. 2023;179:79-84.
    >> Share

  375. WICKENHEISSER NE, Dillon M, Broadwater G, Zacherl K, et al
    Radical hysterectomy case volume and cervical cancer treatment in the era of COVID-19: A multi-site analysis of National Cancer Institute-designated Comprehensive Cancer Centers.
    Gynecol Oncol. 2023;179:70-78.
    >> Share

  376. SUMMEY R, Benoit M, Williams-Brown MY
    Survival differences by race and surgical approach in early-stage operable cervical Cancer.
    Gynecol Oncol. 2023;179:63-69.
    >> Share

  377. OPHEIM LO, Engeskaug I, Bjerre Trent PK, Thorsen L, et al
    Associations between modifiable lifestyle factors and health-related quality of life among endometrial carcinoma survivors - A cross-sectional study.
    Gynecol Oncol. 2023;179:52-62.
    >> Share

  378. UCCELLA S, Bosco M, Mezzetto L, Garzon S, et al
    Major vessel resection for complete cytoreduction in primary advanced and recurrent ovarian malignancies: A case series and systematic review of the literature - pushing the boundaries in oncovascular surgery.
    Gynecol Oncol. 2023;179:42-51.
    >> Share

  379. ALIMENA S, Elias KM
    How does mobile health engagement technology help gynecologic oncology patients recover from surgery, affect health equity, and impact healthcare costs?
    Gynecol Oncol. 2023;178:A1-A3.
    >> Share

  380. MICHENER CM, Ricci S, AlHilli M, Beffa L, et al
    Safety and efficacy of topical artesunate for the treatment of vulvar intraepithelial neoplasia 2/3.
    Gynecol Oncol. 2023;178:102-109.
    >> Share

  381. CHEN F, Zhang GN, Lei W, Zhou SG, et al
    Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study.
    Gynecol Oncol. 2023;178:8-13.
    >> Share

    October 2023
  382. CRITELLI P, Pezzulla D, Lillo S, Arpa D, et al
    Outcomes and toxicity in re-irradiation of gynecologic cancer: Systematic review of the Italian association of radiation and clinical oncology (AIRO).
    Gynecol Oncol. 2023;179:33-41.
    >> Share

  383. KIM JH, Kim SI, Park EY, Ha HI, et al
    Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;179:24-32.
    >> Share

  384. RANDALL LM, O'Malley DM, Monk BJ, Coleman RL, et al
    Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
    Gynecol Oncol. 2023;178:161-169.
    >> Share

  385. PRAISS AM, Marra A, Zhou Q, Rios-Doria E, et al
    TERT promoter mutations and gene amplification in endometrial cancer.
    Gynecol Oncol. 2023;179:16-23.
    >> Share

  386. LI S, Zhang X, Zhang T, Zhang R, et al
    Survival outcomes and establishment of a novel risk stratification system in patients with ovarian yolk sac tumors.
    Gynecol Oncol. 2023;178:145-152.
    >> Share

  387. RIOS-DORIA E, Cun HT, Filippova OT, Mueller JJ, et al
    Isolated vaginal recurrence in women with stage I endometrial cancer.
    Gynecol Oncol. 2023;179:9-15.
    >> Share

  388. BAETEN IGT, Hoogendam JP, Schreuder HWR, Jurgenliemk-Schulz IM, et al
    Introducing a novice surgeon to an experienced robotic gynaecological oncology team: An observational cohort study on the impact of a structured curriculum on outcomes of cervical cancer surgery.
    Gynecol Oncol. 2023;178:153-160.
    >> Share

  389. BRZEZINSKA B, Mysona DP, Richardson KP, Rungruang B, et al
    High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
    Gynecol Oncol. 2023;179:1-8.
    >> Share

  390. CHAPMAN GC, Smrz SA, Gordon JC, Lynam SK, et al
    Gynecologic cancer care in the first year of the COVID-19 pandemic.
    Gynecol Oncol. 2023;178:138-144.
    >> Share

  391. FELIX AS, Sinnott JA, Cohn DE, Duggan MA, et al
    Intraluminal tumor cells and prognostic accuracy of endometrial cancer stage criteria: A multi-institution study.
    Gynecol Oncol. 2023;178:130-137.
    >> Share

  392. LEDERMANN JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
    Gynecol Oncol. 2023;178:119-129.
    >> Share

  393. IMTERAT M, Gebers G, Heitz F, Schneider S, et al
    Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study.
    Gynecol Oncol. 2023;178:96-101.
    >> Share

  394. HAN SN, Oza A, Colombo N, Oaknin A, et al
    A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
    Gynecol Oncol. 2023;178:110-118.
    >> Share

  395. MCLAUGHLIN HD, Greco P, Straubhar AM, Rolston A, et al
    Implementation of routine venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
    Gynecol Oncol. 2023;178:89-95.
    >> Share

  396. KOBEL M, Yang RZ, Kang EY, Al-Shamma Z, et al
    Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
    Gynecol Oncol. 2023;178:80-88.
    >> Share

  397. NGUYEN NT, Raetz A, Montoya D, Schilling V, et al
    Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
    Gynecol Oncol. 2023;178:69-79.
    >> Share

  398. JORGENSEN K, Denham C, Kanbergs A, Wu CF, et al
    All-cause and cancer-specific mortality after fertility-sparing surgery for stage IA and IC epithelial ovarian cancer.
    Gynecol Oncol. 2023;178:60-68.
    >> Share

  399. PLOTKIN A, Olkhov-Mitsel E, Nofech-Mozes S, Djordjevic B, et al
    Budget impact analysis of molecular subtype profiling in endometrial cancer.
    Gynecol Oncol. 2023;178:54-59.
    >> Share

    September 2023
  400. WHELAN K, Dillon M, Strickland KC, Pothuri B, et al
    TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
    Gynecol Oncol. 2023;178:44-53.
    >> Share

  401. KOBAYASHI-KATO M, Fujii E, Asami Y, Ahiko Y, et al
    Utility of the revised FIGO2023 staging with molecular classification in endometrial cancer.
    Gynecol Oncol. 2023;178:36-43.
    >> Share

  402. ZAMMARRELLI WA 3RD, Ma W, Espino K, Gordhandas S, et al
    Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
    Gynecol Oncol. 2023;178:27-35.
    >> Share

  403. BOITANO TKL, Gardner A, Chu DI, Leath CA 3rd, et al
    Use of a mobile health patient engagement technology improves perioperative outcomes in gynecologic oncology patients.
    Gynecol Oncol. 2023;178:23-26.
    >> Share

  404. HAIGHT PJ, Kistenfeger Q, Riedinger CJ, Khadraoui W, et al
    The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
    Gynecol Oncol. 2023;178:14-22.
    >> Share

  405. BLACK KA, Nelson G, Goucher N, Foley J, et al
    Effect of transversus abdominis plane block on postoperative outcomes in gynecologic oncology patients managed on an Enhanced Recovery After Surgery pathway.
    Gynecol Oncol. 2023;178:1-7.
    >> Share

  406. MARSH LA, Kim TH, Zhang M, Kubalanza K, et al
    Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
    Gynecol Oncol. 2023;177:173-179.
    >> Share

  407. WRIGHT AA, Poort H, Tavormina A, Schmiege SJ, et al
    Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
    Gynecol Oncol. 2023;177:165-172.
    >> Share

  408. AGUSTI N, Viveros-Carreno D, Mora-Soto N, Ramirez PT, et al
    Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;177:157-164.
    >> Share

  409. HUI C, Mendoza MG, von Eyben R, Dorigo O, et al
    Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?
    Gynecol Oncol. 2023;177:150-156.
    >> Share

  410. LEE HC, Jeong JW, Lee JH, Kim SH, et al
    High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial.
    Gynecol Oncol. 2023;177:142-149.
    >> Share

  411. TOBONI MD, Wu S, Farrell A, Xiu J, et al
    Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.
    Gynecol Oncol. 2023;177:132-141.
    >> Share

  412. DUUS AH, Zheng G, Baandrup L, Faber MT, et al
    Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on histology and time since the procedure.
    Gynecol Oncol. 2023;177:125-131.
    >> Share

  413. MOUFARRIJ S, Havrilesky L, Jewell EL
    Universal thromboprophylaxis in ovarian cancer patients before and after surgery?
    Gynecol Oncol. 2023;176:A1-A2.
    >> Share

  414. BRUCE KH, Alabaster A, Tran AM
    Vulvar cancer survival by primary treatment modality: A retrospective cohort study.
    Gynecol Oncol. 2023;176:173-178.
    >> Share

  415. PRAISS AM, Allison D, Tessier-Cloutier B, Flynn J, et al
    Extensive versus focal lymphovascular invasion in squamous cell carcinoma of the cervix: A comprehensive international, multicenter, retrospective clinicopathologic study.
    Gynecol Oncol. 2023;176:147-154.
    >> Share

  416. MCGONIGAL S, Wu R, Grimley E, Turk EG, et al
    A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
    Gynecol Oncol. 2023;176:139-146.
    >> Share

  417. LIU Y, Chen J, Lu Z, Chang X, et al
    Clinicopathological analysis of patients with molecularly confirmed stage I adult granulosa cell tumors and prediction of recurrence.
    Gynecol Oncol. 2023;176:106-114.
    >> Share

  418. LIM H, Ju Y, Kim SI, Park JH, et al
    Clinical implications of histologic subtypes on survival outcomes in primary mucinous ovarian carcinoma.
    Gynecol Oncol. 2023;177:117-124.
    >> Share

  419. SPAGNOL G, Marchetti M, De Tommasi O, Vitagliano A, et al
    Simple rules, O-RADS, ADNEX and SRR model: Single oncologic center validation of diagnostic predictive models alone and combined (two-step strategy) to estimate the risk of malignancy in adnexal masses and ovarian tumors.
    Gynecol Oncol. 2023;177:109-116.
    >> Share

    August 2023
  420. ANDRIANI L, Oh J, McMinn E, Gleason E, et al
    Telehealth utilization in gynecologic oncology clinical trials.
    Gynecol Oncol. 2023;177:103-108.
    >> Share

  421. NASIOUDIS D, Fernandez ML, Wong N, Powell DJ Jr, et al
    The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
    Gynecol Oncol. 2023;177:86-94.
    >> Share

  422. NARAYAN P, Ahsan MD, Webster EM, Perez L, et al
    Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;177:72-85.
    >> Share

  423. BLITZER GC, Zhao SG, Bradley KA, Hartenbach EM, et al
    The role of ctDNA in endometrial cancer: A tool for risk stratification and disease monitoring.
    Gynecol Oncol. 2023 Aug 28:S0090-8258(23)01437.
    >> Share

  424. AO W, Kim HI, Tommarello D, Conrads KA, et al
    Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
    Gynecol Oncol. 2023;177:60-71.
    >> Share

  425. MARJON N, Guerra R, Freeman A, Mak J, et al
    Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer.
    Gynecol Oncol. 2023;177:53-59.
    >> Share

  426. MORTON M, McLaughlin EM, Calo CA, Lightfoot M, et al
    Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?
    Gynecol Oncol. 2023;177:46-52.
    >> Share

  427. HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
    Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
    Gynecol Oncol. 2023;177:38-45.
    >> Share

  428. KIM JH, Park KN, Park EY, Jang MJ, et al
    Impact of warm saline irrigation, hyperthermic intraperitoneal chemotherapy on postoperative pain in primary ovarian cancer from the KOV-HIPEC-01 randomized trial.
    Gynecol Oncol. 2023;177:32-37.
    >> Share

  429. PIGNATA S, Bookman M, Sehouli J, Miller A, et al
    Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
    Gynecol Oncol. 2023;177:20-31.
    >> Share

  430. NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
    Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
    Gynecol Oncol. 2023;177:14-19.
    >> Share

  431. HOLTZMAN S, Wang K, Saleh M, Papatla K, et al
    Letters of recommendation for gynecologic oncology fellowship differ by gender and race.
    Gynecol Oncol. 2023;177:9-13.
    >> Share

  432. WONG NKY, Llaurado Fernandez M, Kommoss FKF, Praveen Kumar P, et al
    Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.
    Gynecol Oncol. 2023;176:162-172.
    >> Share

  433. KOROMPELIS P, Rundle S, Cassar V, Ratnavelu N, et al
    "Conservative surgical approaches for small volume FIGO stage IB1 cervical cancer. Updated survival and obstetric outcomes of an expanded cohort".
    Gynecol Oncol. 2023;176:155-161.
    >> Share

  434. LEUNG E, Tremblay C, Liao D, Burnett M, et al
    Treatment patterns and outcomes of patients with locally advanced vulvar or vaginal cancer in British Columbia.
    Gynecol Oncol. 2023;175:107-113.
    >> Share

  435. JAMIESON A, McConechy MK, Lum A, Leung S, et al
    Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.
    Gynecol Oncol. 2023;175:45-52.
    >> Share

  436. GARRETT AA, Ricciuti J, Lang SM, Burriss ME, et al
    Feasibility of intraoperative injection of radioactive tracer and blue dye for sentinel lymph node biopsy in vulvar cancer.
    Gynecol Oncol. 2023;175:41-44.
    >> Share

  437. TAYLOR DD, Gercel-Taylor C, Parker LP
    Retraction notice to "Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology Volume 115, Issue 1, October 2009, Pages 112-120].
    Gynecol Oncol. 2023;175:193.
    >> Share

  438. TAYLOR DD, Gercel-Taylor C
    Retraction notice to "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer" [Gynecologic Oncology, Volume 110, Issue 1, July 2008, Pages 13-21].
    Gynecol Oncol. 2023;175:192.
    >> Share

    July 2023
  439. BRAGA A, Lopes R, Campos V, Freitas F, et al
    The impact of the distance traveled between residence and gestational trophoblastic neoplasia reference center and clinical outcomes in Brazilian women.
    Gynecol Oncol. 2023;176:130-138.
    >> Share

  440. KONG TW, Kim J, Son JH, Lee AJ, et al
    Is minimally invasive radical surgery safe for patients with cervical cancer
    Gynecol Oncol. 2023;176:122-129.
    >> Share

  441. SAITO A, Nishikawa T, Yoshida H, Mizoguchi C, et al
    Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
    Gynecol Oncol. 2023;176:115-121.
    >> Share

  442. MERCADEL AJ, Sanchez-Covarrubias AP, Medina HN, Pinheiro PS, et al
    Intra-racial disaggregation reveals associations between nativity and overall survival in women with endometrial cancer.
    Gynecol Oncol. 2023;176:98-105.
    >> Share

  443. HORVAT N, Causa Andrieu P, Meier A, Ji X, et al
    A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma.
    Gynecol Oncol. 2023;176:90-97.
    >> Share

  444. KIKUCHI A, Yoshida H, Tsuda H, Nishio S, et al
    Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study from the Japanese Clinical Oncology Group.
    Gynecol Oncol. 2023;176:82-89.
    >> Share

  445. DOS SANTOS MV, Holth A, Lindemann K, Staff AC, et al
    Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
    Gynecol Oncol. 2023;176:76-81.
    >> Share

  446. SIA TY, Manning-Geist BL, Ehmann S, Lavery JA, et al
    Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2023;176:69-75.
    >> Share

  447. EIDE AJ, Halle MK, Lura N, Fasmer KE, et al
    Visceral fat percentage for prediction of outcome in uterine cervical cancer.
    Gynecol Oncol. 2023;176:62-68.
    >> Share

  448. MOREIRA I, Ferreira M, Garcia S, Novais P, et al
    Practical lessons learned from real-world implementation of the molecular classification for endometrial carcinoma.
    Gynecol Oncol. 2023;176:53-61.
    >> Share

  449. ZHANG Y, Chu R, Zhang Z, Xu C, et al
    Prognostic significance of positive peritoneal cytology in endometrial carcinoma based on ESGO/ESTRO/ESP risk classification: A multicenter retrospective study.
    Gynecol Oncol. 2023;176:43-52.
    >> Share

  450. SHAFA A, Watkins AB, McGree ME, Weroha SJ, et al
    Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
    Gynecol Oncol. 2023;176:36-42.
    >> Share

  451. ESPANOL P, Rovira R, Caruana P, Luna-Guibourg R, et al
    Dopamine receptors D1 and D2 show prognostic significance and potential therapeutic applications for endometrial cancer patients.
    Gynecol Oncol. 2023;176:25-35.
    >> Share

  452. O'CEARBHAILL RE, Miller A, Soslow RA, Lankes HA, et al
    A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
    Gynecol Oncol. 2023;176:16-24.
    >> Share

  453. KAHVECIOGLU A, Gurlek E, Yedekci FY, Sari SY, et al
    Simultaneous integrated or sequential boost to clinically involved lymph nodes in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy.
    Gynecol Oncol. 2023;176:10-15.
    >> Share

  454. GE J, Fader AN, Dudley JC
    Early detection of endometrial cancer.
    Gynecol Oncol. 2023;174:A1-A2.
    >> Share

    June 2023
  455. KONSKI A, Deshmukh S, Klopp AH, Yeung AR, et al
    Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203.
    Gynecol Oncol. 2023;175:176-181.
    >> Share

  456. BURKETT WC, Iwai Y, Gehrig PA, Knittel AK, et al
    Fractured and delayed: A qualitative analysis of disruptions in care for gynecologic malignancies during incarceration.
    Gynecol Oncol. 2023;176:1-9.
    >> Share

  457. MAH SJ, Carter Ramirez DM, Eiriksson LR, Schnarr K, et al
    Palliative care utilization across health sectors for patients with gynecologic malignancies in Ontario, Canada from 2006 to 2018.
    Gynecol Oncol. 2023;175:169-175.
    >> Share

  458. TAYLOR KN, Li A, Manuel M, Rimel BJ, et al
    The association of black race with receipt of hysterectomy and survival in low-risk endometrial cancer.
    Gynecol Oncol. 2023;175:156-162.
    >> Share

  459. FEINBERG J, Zivanovic O, Hannon M, McCready T, et al
    Patient-reported symptoms after minimally invasive hysterectomy and association with postoperative complications.
    Gynecol Oncol. 2023;175:163-168.
    >> Share

  460. MORTON M, Patterson J, Sciuva J, Perni J, et al
    Malnutrition, sarcopenia, and cancer cachexia in gynecologic cancer.
    Gynecol Oncol. 2023;175:142-155.
    >> Share

  461. LI J, Xue X, Zhang Y, Ding F, et al
    The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
    Gynecol Oncol. 2023;175:133-141.
    >> Share

  462. SAINI A, Suh L, Gao J, Leung K, et al
    Intra-operative tumor spillage in minimally invasive surgery for endometrial cancer and its impact on recurrence risk.
    Gynecol Oncol. 2023;175:128-132.
    >> Share

  463. SMITH AJB, Puttaraju T, Applebaum J, Fader AN, et al
    Long-term impact of the Affordable Care Act's dependent coverage mandate on young women with gynecologic cancer.
    Gynecol Oncol. 2023;175:121-127.
    >> Share

  464. COLOMBO N, Gadducci A, Landoni F, Lorusso D, et al
    Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
    Gynecol Oncol. 2023 Jun 22:S0090-8258(23)00306.
    >> Share

  465. ANDERSON C, Peery AF, Bae-Jump VL, Brewster WR, et al
    Gastrointestinal outcomes among older women with endometrial cancer.
    Gynecol Oncol. 2023;175:114-120.
    >> Share

  466. ZHENG S, Wu Y, Donnelly ED, Strauss JB, et al
    A cost-effective, machine learning-based new unified risk-classification score (NU-CATS) for patients with endometrial cancer.
    Gynecol Oncol. 2023;175:97-106.
    >> Share

  467. GWACHAM NI, Kilowski KA, Recio FO, Awada A, et al
    Malignant peritoneal cytologic contamination with robotic hysterectomy for endometrial cancer.
    Gynecol Oncol. 2023;175:93-96.
    >> Share

  468. WILEY RL, Urbauer DL, Nugent E, Gallegos J, et al
    Endometrial cancer patients understanding and interest in weight loss surgery.
    Gynecol Oncol. 2023;175:88-92.
    >> Share

  469. MORTON M, Haight PJ, Khadraoui W, Backes F, et al
    "More than a song and dance": Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok.
    Gynecol Oncol. 2023;175:81-87.
    >> Share

  470. BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al
    Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study.
    Gynecol Oncol. 2023;175:72-80.
    >> Share

  471. WINTER MC, Tidy JA, Singh K, Sarwar N, et al
    Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
    Gynecol Oncol. 2023;175:66-71.
    >> Share

  472. SILBERMAN JN, Bercow AS, Gockley AA, Eisenhauer EL, et al
    Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
    Gynecol Oncol. 2023;175:60-65.
    >> Share

  473. KULKARNI A, Chen L, Gockley A, Khoury-Collado F, et al
    Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals.
    Gynecol Oncol. 2023;175:53-59.
    >> Share

  474. HAIGHT PJ, Riedinger CJ, Backes FJ, O'Malley DM, et al
    The right time for change: A report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria.
    Gynecol Oncol. 2023;175:32-40.
    >> Share

  475. POTHURI B, Blank SV, Myers TK, Hines JF, et al
    Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
    Gynecol Oncol. 2023;174:278-287.
    >> Share

  476. SMITH AJB, Alvarez R, Heintz J, Simpkins F, et al
    Disparities in clinical trial participation in ovarian cancer: A real-world analysis.
    Gynecol Oncol. 2023;175:25-31.
    >> Share

  477. KARPEL HC, Smith M, Brodsky A, Pothuri B, et al
    Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancer.
    Gynecol Oncol. 2023;175:20-24.
    >> Share

  478. NICHOLSON K, Macharia A, Furuya R, Manning C, et al
    Association of body mass index with early age at diagnosis of endometrial intraepithelial neoplasia.
    Gynecol Oncol. 2023;175:15-19.
    >> Share

  479. BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
    Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
    Gynecol Oncol. 2023 Jun 2:S0090-8258(23)00299.
    >> Share

  480. HOLTZMAN S, Stoffels G, Flint M, Carr C, et al
    Outcomes for patients with high-risk endometrial cancer undergoing sentinel lymph node assessment versus full lymphadenectomy.
    Gynecol Oncol. 2023;174:273-277.
    >> Share

  481. LJUNGQVIST O
    Gynecologic oncology surgery - Ready for the next step in ERAS.
    Gynecol Oncol. 2023;173:A1-A2.
    >> Share

  482. LEVINE MD, Barrington DA, Meade CE, Lammers SM, et al
    Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
    Gynecol Oncol. 2023;173:15-21.
    >> Share

    May 2023
  483. SIA TY, Basaran D, Dagher C, Sassine D, et al
    Laparoscopy with or without robotic assistance does not negatively impact long-term oncologic outcomes in patients with uterine serous carcinoma.
    Gynecol Oncol. 2023;175:8-14.
    >> Share

  484. PEIPERT JD, Goble S, Isaacson J, Tang X, et al
    Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
    Gynecol Oncol. 2023;175:1-7.
    >> Share

  485. RIOS-DORIA E, Momeni-Boroujeni A, Friedman CF, Selenica P, et al
    Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
    Gynecol Oncol. 2023;174:262-272.
    >> Share

  486. PETERS PN, Havrilesky LJ, Davidson BA
    Guidelines for goals of care discussions in patients with gynecologic cancer.
    Gynecol Oncol. 2023;174:247-252.
    >> Share

  487. SCHIFFMAN M, Mirabello L, Egemen D, Befano B, et al
    The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.
    Gynecol Oncol. 2023;174:253-261.
    >> Share

  488. EMBABY A, Kutzera J, Geenen JJ, Pluim D, et al
    WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
    Gynecol Oncol. 2023;174:239-246.
    >> Share

  489. KIM J, Kim SI, Kim NR, Kim H, et al
    Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
    Gynecol Oncol. 2023;174:231-238.
    >> Share

  490. KIM NR, Kim SI, Suh DH, Kim HS, et al
    Survival outcomes of laparoscopic versus open radical hysterectomy in early cervical cancer with incidentally identified high-risk factors.
    Gynecol Oncol. 2023;174:224-230.
    >> Share

  491. PRAISS AM, Miller A, Smith J, Lichtman SM, et al
    Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
    Gynecol Oncol. 2023;174:213-223.
    >> Share

  492. DEMARI JA, Dressler EV, Foraker RE, Wells BJ, et al
    Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA).
    Gynecol Oncol. 2023;174:208-212.
    >> Share

  493. EURICH K, De La Cruz P, Laguna A, Woodman M, et al
    Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer.
    Gynecol Oncol. 2023;174:200-207.
    >> Share

  494. HANVIC B, Lecuru F, Vanacker H, Pautier P, et al
    Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salome study including 469 patients. A TMRG and GINECO group study.
    Gynecol Oncol. 2023;174:190-199.
    >> Share

  495. KNIPPRATH-MESZAROS AM, Tozzi A, Butenschon A, Reina H, et al
    High negative prediction for the Basel sarcoma score: Sonographic assessment of features suspicious of uterine sarcoma.
    Gynecol Oncol. 2023;174:182-189.
    >> Share

  496. QIU Y, Zha J, Ma A, Zhou T, et al
    Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2023;174:175-181.
    >> Share

  497. HAN L, Chen Y, Zheng A, Chen H, et al
    Effect of preoperative cervical conization before hysterectomy on survival and recurrence of patients with cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;174:167-174.
    >> Share

  498. RIMEL BJ, Crane EK, Hou J, Nakayama J, et al
    Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations.
    Gynecol Oncol. 2023;174:148-156.
    >> Share

  499. FENG Z, Fu Y, Li R, Li H, et al
    Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of epithelial ovarian cancer patients.
    Gynecol Oncol. 2023;174:142-147.
    >> Share

  500. THOMSON JP, Hollis RL, van Baal J, Ilenkovan N, et al
    Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
    Gynecol Oncol. 2023;174:157-166.
    >> Share

  501. XU Z, Yang B, Shan W, Liao J, et al
    Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: A prospective, open-label, randomized controlled phase II study.
    Gynecol Oncol. 2023;174:133-141.
    >> Share

  502. KIM SR, Madariaga A, Hogen L, Vicus D, et al
    Safety of fertility sparing management in invasive mucinous ovarian carcinoma.
    Gynecol Oncol. 2023;174:129-132.
    >> Share

  503. WITJES VM, Ligtenberg MJL, Vos JR, Braspenning JCC, et al
    The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
    Gynecol Oncol. 2023;174:121-128.
    >> Share

  504. MOYETT JM, Howell EP, Broadwater G, Greene M, et al
    Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score.
    Gynecol Oncol. 2023;174:114-120.
    >> Share

  505. NEWCOMER MM, Dorayappan KDP, Wagner V, Suarez AA, et al
    Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles.
    Gynecol Oncol. 2023;173:138-150.
    >> Share

  506. BEAVIS AL, Blechter B, Najjar O, Fader AN, et al
    Identifying women 45 years and younger at elevated risk for endometrial hyperplasia or cancer.
    Gynecol Oncol. 2023;174:98-105.
    >> Share

  507. LEE AJ, Yang EJ, Kim NK, Kim Y, et al
    Fertility-sparing hormonal treatment in patients with stage I endometrial cancer of grade 2 without myometrial invasion and grade 1-2 with superficial myometrial invasion: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-2001).
    Gynecol Oncol. 2023;174:106-113.
    >> Share

  508. ALGERA MD, Slangen BFM, van Driel WJ, Wouters MWJM, et al
    Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study.
    Gynecol Oncol. 2023;174:89-97.
    >> Share

  509. VERGOTE I, Van Nieuwenhuysen E, Casado A, Laenen A, et al
    Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
    Gynecol Oncol. 2023;174:80-88.
    >> Share

  510. ROBOVA H, Rob L, Halaska MJ, Drozenova J, et al
    Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Pregnancy outcomes.
    Gynecol Oncol. 2023;174:76-79.
    >> Share

  511. FU H, Zhang J, Zhao S, He N, et al
    Survival outcomes of robotic-assisted laparoscopy versus conventional laparoscopy and laparotomy for endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;174:55-67.
    >> Share

  512. DI DONATO V, Bogani G, Casarin J, Ghezzi F, et al
    Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for "low-risk" early-stage cervical cancer: A propensity-score based analysis.
    Gynecol Oncol. 2023;174:49-54.
    >> Share

  513. HUI C, Mendoza MG, Snyder J, Dorigo O, et al
    Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control.
    Gynecol Oncol. 2023;174:42-48.
    >> Share

  514. SIA TY, Gordhandas SB, Birsoy O, Kemel Y, et al
    Germline drivers of gynecologic carcinosarcomas.
    Gynecol Oncol. 2023;174:34-41.
    >> Share

  515. STOLER MH, Parvu V, Yanson K, Andrews J, et al
    Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Gynecol Oncol. 2023;174:68-75.
    >> Share

  516. SIA TY, Tew WP, Purdy C, Chi DS, et al
    The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
    Gynecol Oncol. 2023;173:130-137.
    >> Share

  517. CORONADO PJ, Alonso-Espias M, Yildirim Y, Macuks R, et al
    Lymph node dissection in uterine leiomyosarcomas: A matched-pair study.
    Gynecol Oncol. 2023;174:28-33.
    >> Share

  518. PIEDIMONTE S, Helpman L, Pond G, Nelson G, et al
    Surgical margin status in relation to surgical approach in the management of early-stage cervical Cancer: A Canadian cervical Cancer collaborative (4C) study.
    Gynecol Oncol. 2023;174:21-27.
    >> Share

  519. BAKKUM-GAMEZ JN, Sherman ME, Slettedahl SW, Mahoney DW, et al
    Detection of endometrial cancer using tampon-based collection and methylated DNA markers.
    Gynecol Oncol. 2023;174:11-20.
    >> Share

  520. SAMUEL D, Kwon D, Huang M, Zhao W, et al
    Disparities in refusal of surgery for gynecologic cancer.
    Gynecol Oncol. 2023;174:1-10.
    >> Share

  521. FUREY KB, Anderson ZS, Kuznicki ML, Klar M, et al
    Increasing trends of cervical conization with lymph node evaluation for fertility-sparing surgery in early cervical cancer.
    Gynecol Oncol. 2023;173:122-129.
    >> Share

  522. BEDNAR EM, Chen M, Walsh MT Jr, Eppolito AL, et al
    Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems.
    Gynecol Oncol. 2023;172:106-114.
    >> Share

  523. VESTERGAARD AHS, Neergaard MA, Fokdal LU, Christiansen CF, et al
    Utilisation of hospital-based specialist palliative care in patients with gynaecological cancer: Temporal trends, predictors and association with high-intensity end-of-life care.
    Gynecol Oncol. 2023;172:1-8.
    >> Share

    April 2023
  524. HANDLEY KF, Mehta S, Martin AL, Biswas S, et al
    Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma.
    Gynecol Oncol. 2023;173:114-121.
    >> Share

  525. PEREZ L, Webster E, Bull L, Brewer JT, et al
    Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.
    Gynecol Oncol. 2023;173:106-113.
    >> Share

  526. GAUDUCHON T, Kfoury M, Lorusso D, Floquet A, et al
    PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
    Gynecol Oncol. 2023;173:98-105.
    >> Share

  527. KIM SI, Nam SH, Hwangbo S, Kim Y, et al
    Conization before radical hysterectomy in patients with early-stage cervical cancer: A Korean multicenter study (COBRA-R).
    Gynecol Oncol. 2023;173:88-97.
    >> Share

  528. ORELLANA TJ, Kim H, Beriwal S, Taylor SE, et al
    Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer.
    Gynecol Oncol. 2023;173:81-87.
    >> Share

  529. KANG OJ, Nam JH, Park JY
    Laparo-endoscopic single-site versus conventional laparoscopic surgery for early-stage endometrial cancer: A randomized controlled non-inferiority trial.
    Gynecol Oncol. 2023;173:74-80.
    >> Share

  530. SCANLON LR, Khaksari B, Goel S, Nevadunsky NS, et al
    Direct oral anticoagulant (DOACs) prescribing practices of members of the Society of Gynecologic Oncology and American Society of Clinical Oncology.
    Gynecol Oncol. 2023;173:68-73.
    >> Share

  531. NELSON G, Fotopoulou C, Taylor J, Glaser G, et al
    Enhanced recovery after surgery (ERAS(R)) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update.
    Gynecol Oncol. 2023;173:58-67.
    >> Share

  532. GARCIA-SAYRE J, Lin YG, Matuso K, Tsao-Wei DD, et al
    Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer.
    Gynecol Oncol. 2023;173:49-57.
    >> Share

  533. CIBULA D
    The group with the most heterogenous treatment among patients with cervical cancer.
    Gynecol Oncol. 2023 Apr 17:S0090-8258(23)00169.
    >> Share

  534. MARCHOCKI Z, Cusimano MC, Vicus D, Pulman K, et al
    Diagnostic accuracy of frozen section and patterns of nodal spread in high grade endometrial cancer: A secondary outcome of the SENTOR prospective cohort study.
    Gynecol Oncol. 2023;173:41-48.
    >> Share

  535. CHANG X, Tamauchi S, Yoshida K, Yoshihara M, et al
    Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway.
    Gynecol Oncol. 2023;173:31-40.
    >> Share

  536. PIGNATA S, Oza A, Hall G, Pardo B, et al
    Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
    Gynecol Oncol. 2023;172:121-129.
    >> Share

  537. HERNANDEZ-ZEPEDA ML, Munro EG, Caughey AB, Bruegl AS, et al
    Ovarian preservation compared to oophorectomy in premenopausal women with early-stage, low-grade endometrial Cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2023;173:8-14.
    >> Share

  538. SCHWARTZ ZP, Li AJ, Walsh CS, Rimel BJ, et al
    Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
    Gynecol Oncol. 2023;173:1-7.
    >> Share

  539. MORELL A, Samborski A, Williams D, Anderson E, et al
    Calculating surgical readmission rates in gynecologic oncology: The impact of patient factors.
    Gynecol Oncol. 2023;172:115-120.
    >> Share

    March 2023
  540. BRUCE SF, Wu S, Ribeiro JR, Farrell A, et al
    HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
    Gynecol Oncol. 2023;172:98-105.
    >> Share

  541. BERLIN E, Yegya-Raman N, Garver E, Li T, et al
    Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.
    Gynecol Oncol. 2023;172:92-97.
    >> Share

  542. AREND R, Dholakia J, Castro C, Matulonis U, et al
    DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
    Gynecol Oncol. 2023;172:82-91.
    >> Share

  543. SHALOWITZ DI, Schroeder MC, Birken SA
    An implementation science approach to the systematic study of access to gynecologic cancer care.
    Gynecol Oncol. 2023;172:78-81.
    >> Share

  544. MUSACCHIO L, Turinetto M, Arenare L, Bartoletti M, et al
    Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
    Gynecol Oncol. 2023;172:72-77.
    >> Share

  545. MCNAMARA B, Harold J, Manavella D, Bellone S, et al
    Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
    Gynecol Oncol. 2023;172:65-71.
    >> Share

  546. MOMENI-BOROUJENI A, Vanderbilt C, Yousefi E, Abu-Rustum NR, et al
    Landscape of chromatin remodeling gene alterations in endometrial carcinoma.
    Gynecol Oncol. 2023;172:54-64.
    >> Share

  547. HAPUARACHI B, Tidy JA, Romanowski C, Singh K, et al
    Leptomeningeal disease as a presenting feature of gestational trophoblastic neoplasia: A review and recommendations for management.
    Gynecol Oncol. 2023;172:47-53.
    >> Share

  548. GRUBBS AE, Sinha N, Garg R, Barber EL, et al
    Use of topic modeling to assess research trends in the journal Gynecologic Oncology.
    Gynecol Oncol. 2023;172:41-46.
    >> Share

  549. STRAUBHAR AM, Zhou Q, Iasonos A, Clarke-Pearson DL, et al
    Cross-sectional survey of surgical practices among gynecologic oncologists in the United States.
    Gynecol Oncol. 2023;172:36-40.
    >> Share

  550. OLULORO A, Temkin SM, Jackson J, Swisher EM, et al
    What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women.
    Gynecol Oncol. 2023;172:29-35.
    >> Share

  551. WEI Z, Luy DD, Tang LW, Deng H, et al
    Gamma Knife radiosurgery for gynecologic metastases to the brain: Analysis of pathology, survival, and tumor control.
    Gynecol Oncol. 2023;172:21-28.
    >> Share

  552. OSANN K, Wenzel L, McKinney C, Wagner L, et al
    Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
    Gynecol Oncol. 2023;171:151-158.
    >> Share

  553. SPENARD E, Geerts W, Lin Y, Gien LT, et al
    Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy.
    Gynecol Oncol. 2023;172:9-14.
    >> Share

  554. LECHARTIER C, Bernard J, Renaud MC, Plante M, et al
    Robotic-assisted surgery for endometrial cancer is safe in morbidly and extremely morbidly obese patients.
    Gynecol Oncol. 2023;172:15-20.
    >> Share

  555. TEWARI KS, Sill MW, Birrer MJ, Penson RT, et al
    Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical Cancer: A NRG oncology randomized study.
    Gynecol Oncol. 2023;171:141-150.
    >> Share

  556. HITCHINS MP, Alvarez R, Zhou L, Aguirre F, et al
    MLH1-methylated endometrial cancer under 60 years of age as the "sentinel" cancer in female carriers of high-risk constitutional MLH1 epimutation.
    Gynecol Oncol. 2023;171:129-140.
    >> Share

  557. BJORNHOLT SM, Sponholtz SE, Mogensen O, Bouchelouche K, et al
    The SENTIREC-endo study - Risks and benefits of a national adoption of sentinel node mapping in low and intermediate risk endometrial cancer.
    Gynecol Oncol. 2023;171:121-128.
    >> Share

  558. MOOLENAAR LR, van Rangelrooij LE, van Poelgeest MIE, van Beurden M, et al
    Clinical outcomes of pelvic exenteration for gynecologic malignancies.
    Gynecol Oncol. 2023;171:114-120.
    >> Share

  559. FOTOPOULOU C
    Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a "pelvic" surgeon.
    Gynecol Oncol. 2023;170:A1-A3.
    >> Share

  560. LEE SS, Karpel HC, Oh C, Smith J, et al
    Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
    Gynecol Oncol. 2023;170:234-240.
    >> Share

  561. COLLARINO A, Fuoco V, Garganese G, Pasciuto T, et al
    Lymphatic mapping and sentinel node biopsy in vulvar melanoma: the first multicenter study and systematic review.
    Gynecol Oncol. 2023;170:153-159.
    >> Share

  562. STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
    Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
    Gynecol Oncol. 2023;170:143-152.
    >> Share

  563. LIU YL, Manning-Geist BL, Knezevic A, Deng L, et al
    Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
    Gynecol Oncol. 2023;170:93-101.
    >> Share

  564. HAROLD J, Bellone S, Manavell DD, Mutlu L, et al
    Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
    Gynecol Oncol. 2023;170:334.
    >> Share

  565. BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
    A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
    Gynecol Oncol. 2023;171:106-113.
    >> Share

    February 2023
  566. GADDUCCI A, Multinu F, De Vitis LA, Cosio S, et al
    Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gynecol Oncol. 2023;171:95-105.
    >> Share

  567. HENDRIKSE CSE, Theelen PMM, van der Ploeg P, Westgeest HM, et al
    The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;171:83-94.
    >> Share

  568. BLANK SV, Huh WK, Bell M, Dilley S, et al
    Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.
    Gynecol Oncol. 2023;171:76-82.
    >> Share

  569. BENBROOK DM, Deng W, Gold MA, Rai R, et al
    Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study.
    Gynecol Oncol. 2023;171:67-75.
    >> Share

  570. VAN KOL KGG, Ebisch RMF, van der Aa M, Wenzel HB, et al
    The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
    Gynecol Oncol. 2023;171:9-14.
    >> Share

  571. TANG H, Fayomi AP, Bai S, Gupta N, et al
    Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy.
    Gynecol Oncol. 2023;171:49-58.
    >> Share

  572. LI G, Xu W, Li X, Chen M, et al
    Oncogenic SIRT7 inhibits GATA4 transcriptional activity and activates the Wnt signaling pathway in ovarian cancer.
    Gynecol Oncol. 2023;171:39-48.
    >> Share

  573. ALIMENA S, Fallah P, Stephenson B, Feltmate C, et al
    Comparison of Enhanced Recovery After Surgery (ERAS) metrics by race among gynecologic oncology patients: Ensuring equitable outcomes.
    Gynecol Oncol. 2023;171:31-38.
    >> Share

  574. PRAISS AM, Zhou Q, Iasonos A, Moukarzel L, et al
    Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
    Gynecol Oncol. 2023;171:23-30.
    >> Share

  575. DESSOURCES K, Ferrando L, Zhou QC, Iasonos A, et al
    Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype.
    Gynecol Oncol. 2023;171:15-22.
    >> Share

  576. JIANG S, Zhao J, Shi X, Wu H, et al
    Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor.
    Gynecol Oncol. 2023;171:1-8.
    >> Share

  577. JORGENSEN K, Melamed A, Wu CF, Nitecki R, et al
    Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
    Gynecol Oncol. 2023 Feb 10:S0090-8258(23)00017.
    >> Share

  578. O'MALLEY DM, Ledermann JA, Coleman RL
    Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".
    Gynecol Oncol. 2023 Feb 9:S0090-8258(23)00049.
    >> Share

  579. KIM C, Salvo G, Ishikawa M, Chen TC, et al
    The role of postoperative radiation after radical hysterectomy for women with early-stage neuroendocrine carcinoma of the cervix: A meta-analysis.
    Gynecol Oncol. 2023;170:328-332.
    >> Share

  580. LIANG MI, Harrison R, Aviki EM, Esselen KM, et al
    Financial toxicity: A practical review for gynecologic oncology teams to understand and address patient-level financial burdens.
    Gynecol Oncol. 2023;170:317-327.
    >> Share

  581. KISSEL M, Balaya V, Guani B, Magaud L, et al
    Impact of preoperative brachytherapy followed by radical hysterectomy in stage IB2 (FIGO 2018) cervical cancer: An analysis of SENTICOL I-II trials.
    Gynecol Oncol. 2023;170:309-316.
    >> Share

  582. HERZOG TJ, Pignata S, Ghamande SA, Rubio MJ, et al
    Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2023;170:300-308.
    >> Share

  583. WIESER V, Tsibulak I, Reimer DU, Zeimet AG, et al
    An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
    Gynecol Oncol. 2023;170:290-299.
    >> Share

  584. JAMIESON A, Huvila J, Leung S, Chiu D, et al
    Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer.
    Gynecol Oncol. 2023;170:282-289.
    >> Share

  585. JANSEN A, de Jong A, Hoogendam JP, Baeten IGT, et al
    Lymphocele following lymph node dissection in cervical and endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;170:273-281.
    >> Share

  586. KAUR A, Wang S, Kumar A
    Impact of racial disparities on potential years of life lost due to gynecologic cancer in the United States: Trends from 1975 to 2017 based on SEER database.
    Gynecol Oncol. 2023;170:266-272.
    >> Share

  587. KOFOED NG, Falconer H, Vanky H, Johansson H, et al
    Survival and chance of reversal after intestinal stoma formation during cytoreductive surgery for advanced ovarian cancer; a population-based cohort study.
    Gynecol Oncol. 2023;170:259-265.
    >> Share

  588. KOEHLER L, Penz LE, John F, Stenzel A, et al
    Functional and psychosocial quality of life in gynecologic Cancer survivors with and without lymphedema symptoms.
    Gynecol Oncol. 2023;170:254-258.
    >> Share

  589. HOLLOWAY SB, Mercadel AJ, Miller DS, Lea JS, et al
    Isolated para-aortic nodal recurrence after treatment of early stage cervical carcinoma.
    Gynecol Oncol. 2023;170:248-253.
    >> Share

  590. GILBERT L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, et al
    Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2023;170:241-247.
    >> Share

  591. BOITANO TKL, Scarinci IC
    Targeting our efforts: the contribution of an open-access tool to assess geographic distribution of recurrent and metastatic cervical cancer.
    Gynecol Oncol. 2023;169:A1-A2.
    >> Share

  592. BERCOW AS, Rauh-Hain JA, Melamed A, Mazina V, et al
    Association of hospital-level factors with utilization of sentinel lymph node biopsy in patients with early-stage vulvar cancer.
    Gynecol Oncol. 2023;169:47-54.
    >> Share

  593. BRASKY TM, Hade EM, Cohn DE, Newton AM, et al
    Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis.
    Gynecol Oncol. 2023;169:137-146.
    >> Share

    January 2023
  594. STRAUBHAR AM, Stroup C, de Bear O, Dalton L, et al
    Provider compliance with a tailored opioid prescribing calculator in gynecologic surgery.
    Gynecol Oncol. 2023;170:229-233.
    >> Share

  595. DAVIDSON TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, et al
    Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2023;170:221-228.
    >> Share

  596. ZHANG Y, Yang R, Xu C, Zhang Y, et al
    Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study.
    Gynecol Oncol. 2023;170:210-220.
    >> Share

  597. HAIGHT PJ, Barrington DA, Graves SM, Piver RN, et al
    Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient population.
    Gynecol Oncol. 2023;170:203-209.
    >> Share

  598. JAMIESON A, Singh N, Huvila J, Gilks CB, et al
    The continuing evolution of endometrial carcinoma molecular classification: Risk stratification within the No Specific Molecular Profile (NSMP) subtype.
    Gynecol Oncol. 2023 Jan 26:S0090-8258(22)02019.
    >> Share

  599. CIBULA D, Akilli H, Jarkovsky J, van Lonkhuijzen L, et al
    Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.
    Gynecol Oncol. 2023;170:195-202.
    >> Share

  600. FERRON G, De Rauglaudre G, Becourt S, Delanoy N, et al
    Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
    Gynecol Oncol. 2023;170:186-194.
    >> Share

  601. BRAGA A, Andrade T, do Carmo Borges de Souza M, Campos V, et al
    Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception - a retrospective cohort study and lit
    Gynecol Oncol. 2023;170:179-185.
    >> Share

  602. HAN C, McNamara B, Bellone S, Harold J, et al
    The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
    Gynecol Oncol. 2023;170:172-178.
    >> Share

  603. MOUFARRIJ S, Sassine D, Basaran D, Jewell EL, et al
    Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
    Gynecol Oncol. 2023;170:167-171.
    >> Share

  604. MITRIC C, Salman L, Abrahamyan L, Kim SR, et al
    Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;170:133-142.
    >> Share

  605. SUVAAL I, Kirchheiner K, Nout RA, Sturdza AE, et al
    Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy.
    Gynecol Oncol. 2023;170:123-132.
    >> Share

  606. JAREEMIT N, Therasakvichya S, Freitas F, Paiva G, et al
    EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.
    Gynecol Oncol. 2023;170:114-122.
    >> Share

  607. NAVARRO AS, Gomez CM, Angeles MA, Fuzier R, et al
    Open abdominal vacuum pack technique for the management of severe abdominal complications after cytoreductive surgery in ovarian cancer.
    Gynecol Oncol. 2023;170:108-113.
    >> Share

  608. JOHNSON AM, Teoh D, Jewett P, Darst BF, et al
    Genetic variants associated with post-traumatic stress symptoms in patients with gynecologic cancer.
    Gynecol Oncol. 2023;170:102-107.
    >> Share

  609. SMITS A, Ten Eikelder M, Dhanis J, Moore W, et al
    Finding the sentinel lymph node in early cervical cancer: When is unusual not uncommon?
    Gynecol Oncol. 2023;170:84-92.
    >> Share

  610. ORELLANA TJ, Garrett AA, Soong TR, Rives T, et al
    The role of adjuvant treatment for early-stage uterine clear cell carcinomas.
    Gynecol Oncol. 2023;170:77-83.
    >> Share

  611. SHIRLEY J, Lambert P, Nachtigal MW, Altman AD, et al
    A comparison of synoptic reports and dictated reports to enhance and standardize surgical documentation and quality of care in epithelial ovarian cancer.
    Gynecol Oncol. 2023;170:54-58.
    >> Share

  612. TOGAMI S, Tanimoto A, Yanazume S, Tokunaga H, et al
    Evaluation of the one-step nucleic acid amplification assay for detecting lymph node metastasis in patients with cervical and endometrial cancer: A multicenter prospective study.
    Gynecol Oncol. 2023;170:70-76.
    >> Share

  613. LU L, Liu T, Wang S, Li J, et al
    Joint detection of multiple HPV-testing technologies and evaluation of clinicopathological characteristics discriminate between HPV-independent and low-copy HPV-associated cervical squamous cell carcinoma (CSCC) -an analysis of 3869 cases.
    Gynecol Oncol. 2023;170:59-69.
    >> Share

  614. KAHN RM, McMinn E, Yeoshoua E, Boerner T, et al
    Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.
    Gynecol Oncol. 2023;170:46-53.
    >> Share

  615. MAURICIO D, Bellone S, Mutlu L, McNamara B, et al
    Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
    Gynecol Oncol. 2023;170:38-45.
    >> Share

  616. WANG DF, Shi XW, Zhang C, Zhang J, et al
    Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
    Gynecol Oncol. 2023;170:25-31.
    >> Share

  617. KIM JH, Chun SY, Lee DE, Woo YH, et al
    Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).
    Gynecol Oncol. 2023;170:19-24.
    >> Share

  618. THOMSON CA, Crane TE, Miller A, Gold MA, et al
    Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2023;170:11-18.
    >> Share

  619. PETERS PN, Rossi EC
    Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment?
    Gynecol Oncol. 2023;168:A2-A3.
    >> Share

    December 2022
  620. ASIF H, Foley G, Simon M, Roque D, et al
    Analysis of endometrial carcinoma TCGA reveals differences in DNA methylation in tumors from Black and White women.
    Gynecol Oncol. 2022;170:1-10.
    >> Share

  621. DINIZ TP, Menezes JN, Goncalves BT, Faloppa CC, et al
    Can mismatch repair status be added to sentinel lymph node mapping algorithm in endometrioid endometrial cancer?
    Gynecol Oncol. 2022;169:131-136.
    >> Share

  622. EHMANN S, Shay K, Zhou Q, Iasonos A, et al
    Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2022;169:118-124.
    >> Share

  623. CASTELLANO T, Moore K, Ting J, Washington C, et al
    Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.
    Gynecol Oncol. 2022;169:113-117.
    >> Share

  624. LI X, Jiang Z, Lu J, Chen X, et al
    Neoadjuvant chemotherapy followed by radical trachelectomy versus upfront abdominal radical trachelectomy for patients with FIGO 2018 stage IB2 cervical cancer.
    Gynecol Oncol. 2022;169:106-112.
    >> Share

  625. ARMSTRONG DK
    AML and MDS associated with PARP inhibitor treatment of ovarian cancer.
    Gynecol Oncol. 2022 Dec 15:S0090-8258(22)01961.
    >> Share

  626. MANAVELLA DD, McNamara B, Harold J, Bellone S, et al
    Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
    Gynecol Oncol. 2022;169:98-105.
    >> Share

  627. LIN MY, Mileshkin L, McNally O, Kondalsamy-Chennakesavan S, et al
    Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection.
    Gynecol Oncol. 2022;169:91-97.
    >> Share

  628. KAHN R, Filippova O, Gordhandas S, An A, et al
    Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors.
    Gynecol Oncol. 2022;169:85-90.
    >> Share

  629. COLOMBA E, Alexandre J, Le Teuff G, Genestie C, et al
    Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
    Gynecol Oncol. 2022;169:78-84.
    >> Share

  630. BOONE RM, Praiss AM, Huang Y, Melamed A, et al
    Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials.
    Gynecol Oncol. 2022;169:70-77.
    >> Share

  631. RUBINSTEIN MM, Doria ER, Konner J, Lichtman S, et al
    Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
    Gynecol Oncol. 2022;169:64-69.
    >> Share

  632. WOOD N, Morton M, Shah SN, Yao M, et al
    Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer.
    Gynecol Oncol. 2022;169:55-63.
    >> Share

  633. REID HW, Selvan B, Montes de Oca MK, Falkovic M, et al
    "You start feeling comfortable, you just start sharing:" A qualitative study of patient distress screening in Black and White patients with endometrial cancer.
    Gynecol Oncol. 2022;168:166-175.
    >> Share

  634. NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
    Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2022;169:41-46.
    >> Share

  635. PARKER VL, Cushen BF, Hills A, Kandiah K, et al
    Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
    Gynecol Oncol. 2022;169:34-40.
    >> Share

  636. DI DIO C, Bogani G, Di Donato V, Cuccu I, et al
    The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Gynecol Oncol. 2022;169:27-33.
    >> Share

  637. DU J, Cheng Y, Hu D, Xing Y, et al
    A nomogram-based overall survival stratification to identify uterine sarcoma patients without distant metastases who may benefit from adjuvant radiotherapy.
    Gynecol Oncol. 2022;169:17-26.
    >> Share

  638. KIM SR, Ene GEV, Simpson A, Gesink D, et al
    Acceptability of bariatric surgery in people with endometrial cancer and atypical hyperplasia: A qualitative study.
    Gynecol Oncol. 2022;169:12-16.
    >> Share

  639. MATULONIS UA
    The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data.
    Gynecol Oncol. 2022;167:401-403.
    >> Share

  640. EHMANN S, Sassine D, Straubhar AM, Praiss AM, et al
    Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.
    Gynecol Oncol. 2022;167:458-466.
    >> Share

    November 2022
  641. VIEIRA-SERNA S, Viveros-Carreno D, Rodriguez J, Grillo-Ardila CF, et al
    Preoperative brachytherapy for early-stage cervical cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022;169:4-11.
    >> Share

  642. CRUM CP, Yoon JY, Feltmate CM
    Clinical commentary extra-uterine high-grade serous carcinoma: Two pathways, two preventions?
    Gynecol Oncol. 2022;169:1-3.
    >> Share

  643. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
    Gynecol Oncol. 2022 Nov 28:S0090-8258(22)01924.
    >> Share

  644. HAROLD J, Bellone S, Manavella DD, Mutlu L, et al
    Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
    Gynecol Oncol. 2022;168:157-165.
    >> Share

  645. DOSTALEK L, Benesova K, Klat J, Kim SH, et al
    Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project.
    Gynecol Oncol. 2022;168:151-156.
    >> Share

  646. SALINARO JR, Zanolli N, Truong T, Havrilesky LJ, et al
    Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative.
    Gynecol Oncol. 2022;168:144-150.
    >> Share

  647. SHU T, Zhou Z, Bai J, Xiao X, et al
    Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
    Gynecol Oncol. 2022;168:135-143.
    >> Share

  648. AKESSON A, Adok C, Dahm-Kahler P
    Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study.
    Gynecol Oncol. 2022;168:127-134.
    >> Share

  649. KARIA PS, Huang Y, Tehranifar P, Wright JD, et al
    Racial and ethnic differences in type II endometrial cancer mortality outcomes: The contribution of sociodemographic, clinicopathologic, and treatment factors.
    Gynecol Oncol. 2022;168:119-126.
    >> Share

  650. MYSONA D, Dorr K, Ward A, Shaver E, et al
    Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy.
    Gynecol Oncol. 2022;168:114-118.
    >> Share

  651. WESTIN SN, Fu S, Tsimberidou A, Piha-Paul S, et al
    Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
    Gynecol Oncol. 2022;168:76-82.
    >> Share

  652. MATANES E, Amajoud Z, Kogan L, Mitric C, et al
    Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?
    Gynecol Oncol. 2022;168:107-113.
    >> Share

  653. MOUKARZEL LA, Nguyen N, Zhou Q, Iasonos A, et al
    Association of bowel preparation with surgical-site infection in gynecologic oncology surgery: Post-hoc analysis of a randomized controlled trial.
    Gynecol Oncol. 2022;168:100-106.
    >> Share

  654. ZHAO L, Qin Y, Ma D, Liu H, et al
    Corrigendum to "Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia: A retrospective study" [Gynecologic Oncology Volume 167, Issue 3, Oct 2022 Pages 37-41].
    Gynecol Oncol. 2022 Nov 18:S0090-8258(22)01925.
    >> Share

  655. MARK J, Fisher DT, Kim M, Emmons T, et al
    Carboplatin enhances lymphocyte-endothelial interactions to promote CD8(+) T cell trafficking into the ovarian tumor microenvironment.
    Gynecol Oncol. 2022;168:92-99.
    >> Share

  656. YANAIHARA N, Yoshino Y, Noguchi D, Tabata J, et al
    Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
    Gynecol Oncol. 2022;168:83-91.
    >> Share

  657. PHUNG MT, Webb PM, DeFazio A, Fereday S, et al
    Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
    Gynecol Oncol. 2022;168:68-75.
    >> Share

  658. YOU B, Bolze PA, Lotz JP, Massardier J, et al
    Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.
    Gynecol Oncol. 2022;168:62-67.
    >> Share

  659. BRUEGL AS, Emerson J, Tirumala K
    Persistent disparities of cervical cancer among American Indians/Alaska natives: Are we maximizing prevention tools?
    Gynecol Oncol. 2022;168:56-61.
    >> Share

  660. WALSH CS, Hacker KE, Secord AA, DeLair DF, et al
    Molecular testing for endometrial cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2022;168:48-55.
    >> Share

  661. KNAUSS T, Hansen BT, Pedersen K, Aasbo G, et al
    The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial.
    Gynecol Oncol. 2022;168:39-47.
    >> Share

  662. KA K, Laville A, Rassy E, Ayachi RE, et al
    Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: Clinical outcome and prognostic factors.
    Gynecol Oncol. 2022;168:32-38.
    >> Share

  663. MEAGHER NS, Hamilton P, Milne K, Thornton S, et al
    Profiling the immune landscape in mucinous ovarian carcinoma.
    Gynecol Oncol. 2022;168:23-31.
    >> Share

  664. PIAO H, Wu M, Qin S, Tang Z, et al
    Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2022;168:17-22.
    >> Share

  665. KIM H, Kim HJ, Ahn HS
    Does endometriosis increase the risks of endometrial hyperplasia and endometrial cancer?
    Gynecol Oncol. 2022 Nov 7. pii: S0090-8258(22)00425.
    >> Share

  666. KELKAR SS, Prabhu VS, Corman S, Odak S, et al
    Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Gynecol Oncol. 2022 Nov 4. pii: S0090-8258(22)01893.
    >> Share

  667. PETERS PN, Moyett JM, Davidson BA, Cantrell S, et al
    Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction.
    Gynecol Oncol. 2022 Nov 4. pii: S0090-8258(22)01890.
    >> Share

  668. MUELLER JJ, Rios-Doria E, Park KJ, Broach VA, et al
    Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?
    Gynecol Oncol. 2022;168:1-7.
    >> Share

  669. ACKROYD SA, Arguello D, Ramos P, Mahdi H, et al
    Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
    Gynecol Oncol. 2022 Nov 1. pii: S0090-8258(22)01897.
    >> Share

    October 2022
  670. RUBINSTEIN M, Shen S, Monk BJ, Tan DSP, et al
    Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
    Gynecol Oncol. 2022 Oct 21. pii: S0090-8258(22)01889.
    >> Share

  671. O'MALLEY DM, Oza AM, Lorusso D, Aghajanian C, et al
    Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)00575.
    >> Share

  672. KIM SI, Kim JH, Lee S, Cho H, et al
    Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)01887.
    >> Share

  673. JORGE S
    Health Equity in Gynecologic Oncology: Focus on Limited English Proficiency.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)01861.
    >> Share

  674. CHENG A, Rao Q, Liu Y, Huang C, et al
    Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
    Gynecol Oncol. 2022 Oct 18. pii: S0090-8258(22)01888.
    >> Share

  675. HINCHCLIFF E, Rumpf J, Ratan R, Fleming ND, et al
    Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma.
    Gynecol Oncol. 2022 Oct 18. pii: S0090-8258(22)01852.
    >> Share

  676. EBATA T, Yamashita S, Takeshima H, Yoshida H, et al
    DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2022 Oct 14. pii: S0090-8258(22)01881.
    >> Share

  677. FARLEY JH, Brady WE, O'Malley D, Fujiwara K, et al
    A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01862.
    >> Share

  678. CHAN JK, Tian C, Kesterson JP, Richardson MT, et al
    The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01856.
    >> Share

  679. SMITH AJB, Mulugeta-Gordon L, Pena D, Kanter GP, et al
    Prior authorization in gynecologic oncology: An analysis of clinical impact.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01858.
    >> Share

  680. GARZON S, Grassi T, Mariani A, Kollikonda S, et al
    Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01860.
    >> Share

  681. KURNIT KC, Nobre SP, Fellman BM, Iglesias DA, et al
    Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
    Gynecol Oncol. 2022 Oct 12. pii: S0090-8258(22)01853.
    >> Share

  682. ELNAGGAR A, Robins D, Baca Y, Arguello D, et al
    Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
    Gynecol Oncol. 2022 Oct 10. pii: S0090-8258(22)01850.
    >> Share

  683. MITRA D, Farr M, Nagarajan P, Ho J, et al
    Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.
    Gynecol Oncol. 2022 Oct 10. pii: S0090-8258(22)01854.
    >> Share

  684. LORUSSO D, Pignata S, Tamberi S, Mangili G, et al
    Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
    Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01851.
    >> Share

  685. POWELL CB, Laurent C, Garcia C, Hoodfar E, et al
    Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
    Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01857.
    >> Share

  686. VON KARTASCHEW AE, Dahm-Kahler P, Rodriguez-Wallberg KA, Holmberg E, et al
    Hormone replacement in premenopausal women treated with bilateral oophorectomy for ovarian cancer - a nationwide population-based study.
    Gynecol Oncol. 2022 Oct 7. pii: S0090-8258(22)01855.
    >> Share

  687. CAO Y, Viswanathan A
    When is it safe to omit contralateral groin management in unilateral sentinel node-positive early stage vulvar cancer?
    Gynecol Oncol. 2022;167:1-2.
    >> Share

  688. VAN DER KOLK WL, Van der Zee AGJ, Slomovitz BM, Baldwin PJW, et al
    Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.
    Gynecol Oncol. 2022;167:3-10.
    >> Share

  689. PERKINS R, Jeronimo J, Hammer A, Novetsky A, et al
    Comparison of accuracy and reproducibility of colposcopic impression based on a single image versus a two-minute time series of colposcopic images.
    Gynecol Oncol. 2022;167:89-95.
    >> Share

  690. CHEN H, Xiong W, Dong X, Liu Y, et al
    Infection status and survival impact of high-risk human papillomavirus in cervical adenocarcinomas: A systematic review and meta-analysis.
    Gynecol Oncol. 2022;167:129-136.
    >> Share

    September 2022
  691. HELPMAN L, Pond GR, Elit L, Anderson LN, et al
    Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study.
    Gynecol Oncol. 2022 Sep 30. pii: S0090-8258(22)01829.
    >> Share

  692. KONSTANTINOPOULOS PA, Lee JM, Gao B, Miller R, et al
    A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
    Gynecol Oncol. 2022 Sep 30. pii: S0090-8258(22)01839.
    >> Share

  693. HOLM J, Gerke O, Vilstrup MH, Spasojevic D, et al
    Improved stratification of stage-specific survival for cervical uterine cancer by integrating FDG-PET/CT and MRI for lymph node staging in 2018 FIGO classification.
    Gynecol Oncol. 2022 Sep 28. pii: S0090-8258(22)01841.
    >> Share

  694. BUCKLEY E, Mullen MM, Nizamuddin RA, Stein JH, et al
    High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer.
    Gynecol Oncol. 2022 Sep 27. pii: S0090-8258(22)01824.
    >> Share

  695. MAH SJ, Seow H, Schnarr K, Reade CJ, et al
    Trends in quality indicators of end-of-life care for women with gynecologic malignancies in Ontario, Canada.
    Gynecol Oncol. 2022 Sep 23. pii: S0090-8258(22)01822.
    >> Share

  696. EGAN D, Moran B, Wilkinson M, Pinyol M, et al
    CRABP2 - A novel biomarker for high-risk endometrial cancer.
    Gynecol Oncol. 2022 Sep 23. pii: S0090-8258(22)01840.
    >> Share

  697. RIEDINGER CJ, Patterson JM, Backes FJ, O'Malley D, et al
    The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)01828.
    >> Share

  698. YFAT K, Mariam K, Mario B, Hal H, et al
    Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)00574.
    >> Share

  699. GLASER GE, Lara OD, Pothuri B, Grimaldi CG, et al
    Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)01837.
    >> Share

  700. WICKLINE M, Wolpin S, Cho S, Tomashek H, et al
    Usability and acceptability of the electronic self-assessment and care (eSAC) program in advanced ovarian cancer: A mixed methods study.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01825.
    >> Share

  701. BERGER AA, Kawaler EA, Dao F, Misirlioglu S, et al
    The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01827.
    >> Share

  702. RONSINI C, Kohler C, de Franciscis P, La Verde M, et al
    Laparo-assisted vaginal radical hysterectomy as a safe option for minimal invasive surgery in early stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)00580.
    >> Share

  703. LEE YW, Morgan JR, Fiascone S, Perkins RB, et al
    Underscreenng, overscreening, and guideline-adherent cervical cancer screening in a national cohort.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01826.
    >> Share

  704. GERSHENSON DM, Cobb LP, Westin SN, Zhang Y, et al
    Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
    Gynecol Oncol. 2022 Sep 19. pii: S0090-8258(22)00591.
    >> Share

  705. HOU JY, Chapman JS, Kalashnikova E, Pierson W, et al
    Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 15. pii: S0090-8258(22)00590.
    >> Share

  706. CROCE S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, et al
    Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00515.
    >> Share

  707. YU S, Yang R, Xu T, Li X, et al
    Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00589.
    >> Share

  708. RUSH SK, Lees BF, Huang DS, Peterson MF, et al
    Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00577.
    >> Share

  709. KLC TR, Wu S, Wilhite AM, Jones NL, et al
    HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00592.
    >> Share

  710. VREDE SW, Hulsman AMC, Reijnen C, Van de Vijver K, et al
    The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00570.
    >> Share

  711. LI N, Zhu X, Nian W, Li Y, et al
    Blood-based DNA methylation profiling for the detection of ovarian cancer.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00480.
    >> Share

  712. PUJADE-LAURAINE E, Tan DSP, Leary A, Mirza MR, et al
    Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00552.
    >> Share

  713. VAN STEIN RM, Engbersen MP, Stolk T, Lopez-Yurda M, et al
    Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
    Gynecol Oncol. 2022 Sep 7. pii: S0090-8258(22)00576.
    >> Share

  714. MENZIES AV, Usher EC, Hsu FC, Levine EA, et al
    HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
    Gynecol Oncol. 2022 Sep 6. pii: S0090-8258(22)00569.
    >> Share

  715. DAVIDSON BA, Turner TB, Kim KH, Cass I, et al
    SGO and the elephant that is still in the room: Wellness, burnout and gynecologic oncology.
    Gynecol Oncol. 2022 Sep 2. pii: S0090-8258(22)00572.
    >> Share

  716. LAGO V, Segarra-Vidal B, Cappucio S, Angeles MA, et al
    OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery.
    Gynecol Oncol. 2022 Sep 1. pii: S0090-8258(22)00542.
    >> Share

  717. VAN DEN HEERIK ASVM, Aiyer KTS, Stelloo E, Jurgenliemk-Schulz IM, et al
    Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
    Gynecol Oncol. 2022;166:530-537.
    >> Share

  718. MATTSON J, Emerson J, Underwood A, Sun G, et al
    Superficial versus deep inguinal nodal dissection for vulvar cancer staging.
    Gynecol Oncol. 2022;166:465-470.
    >> Share

  719. KUMAR A
    Answering the call: Are we ready for action on frailty in gynecologic oncology?
    Gynecol Oncol. 2022;166:377-378.
    >> Share

    August 2022
  720. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods study.
    Gynecol Oncol. 2022 Aug 31. pii: S0090-8258(22)00573.
    >> Share

  721. BUI A, Gehrig PA, Ghamande S, Rungruang BJ, et al
    Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting.
    Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00551.
    >> Share

  722. MADARIAGA A, Mitchell SA, Pittman T, Wang L, et al
    Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovaria
    Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00544.
    >> Share

  723. BOKKERS K, Frederix GWJ, Velthuizen ME, van der Aa M, et al
    Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
    Gynecol Oncol. 2022 Aug 25. pii: S0090-8258(22)00550.
    >> Share

  724. ANDERSON C, Olshan AF, Bae-Jump VL, Brewster WR, et al
    Cardiovascular disease diagnoses among older women with endometrial cancer.
    Gynecol Oncol. 2022 Aug 22. pii: S0090-8258(22)00553.
    >> Share

  725. LAI YL, Chang CS, Chang K, Kim HS, et al
    Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwan.
    Gynecol Oncol. 2022 Aug 19. pii: S0090-8258(22)00547.
    >> Share

  726. THOMAS QD, Boussere A, Classe JM, Pomel C, et al
    Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
    Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00543.
    >> Share

  727. KIM Y, Kim SI, Kim H, Lee M, et al
    Open versus minimally invasive radical hysterectomy for early cervical cancer: A two-center retrospective cohort study with pathologic review of usual-type adenocarcinoma and adenosquamous carcinoma.
    Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00541.
    >> Share

  728. VAHTERISTO M, Heinavaara S, Anttila A, Sarkeala T, et al
    Alternative cytology triage strategies for primary HPV screening.
    Gynecol Oncol. 2022 Aug 10. pii: S0090-8258(22)00495.
    >> Share

  729. DEMARI JA, Shalowitz DI
    Routine informed consent for mismatch repair testing in endometrial cancers: Review and ethical analysis.
    Gynecol Oncol. 2022 Aug 8. pii: S0090-8258(22)00540.
    >> Share

  730. MOSS KM, Mishra GD, Krejany EO, Hickey M, et al
    What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2022 Aug 3. pii: S0090-8258(22)00513.
    >> Share

  731. ZHAO L, Qin Y, Ma D, Liu H, et al
    Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia: A retrospective study.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00514.
    >> Share

  732. KUMAR A, Wang C, Sheedy SP, McCauley BM, et al
    Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00492.
    >> Share

  733. SHAPIRA-FROMMER R, Mileshkin L, Manzyuk L, Penel N, et al
    Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
    Gynecol Oncol. 2022;166:211-218.
    >> Share

  734. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Corrigendum to "Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer" [Gynecologic Oncology, Volume 165, Issue 2, May 2022, Pages 270-280].
    Gynecol Oncol. 2022;166:370-371.
    >> Share

  735. MARION S, Aviki E, Chino F
    Financial toxicity of surgical treatment for gynecological cancer: A growing malignancy.
    Gynecol Oncol. 2022;166:197-199.
    >> Share

    July 2022
  736. SIVARS L, Hellman K, Crona Guterstam Y, Holzhauser S, et al
    Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00512.
    >> Share

  737. HOARE JI, Hockings H, Saxena J, Silva VL, et al
    A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00511.
    >> Share

  738. ALHOLM Z, He D, Ting J, Zhang YJ, et al
    Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis.
    Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00509.
    >> Share

  739. SHRESTHA P, Poudyal B, Yadollahi S, E Wright D, et al
    A systematic review on the use of artificial intelligence in gynecologic imaging - Background, state of the art, and future directions.
    Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00496.
    >> Share

  740. BOGANI G, Donato VD, Scambia G, Landoni F, et al
    Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer.
    Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00494.
    >> Share

  741. LEWIS GK, Ghaith S, Craver EC, Li Z, et al
    The association of endosalpingiosis with gynecologic malignancy.
    Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00510.
    >> Share

  742. BARRINGTON DA, Calo C, Baek J, Brown M, et al
    Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy.
    Gynecol Oncol. 2022 Jul 27. pii: S0090-8258(22)00482.
    >> Share

  743. KIM YN, Lee D, Cha J, Kang WJ, et al
    Usefulness and potential pitfalls of pre-operative PET-CT in patients with endometrial cancer undergoing one- and two-step sentinel lymph node mapping: Do negative findings on PET-CT negativity really indicate node negativity?
    Gynecol Oncol. 2022 Jul 27. pii: S0090-8258(22)00487.
    >> Share

  744. JOLY F, Fabbro M, Berton D, Lequesne J, et al
    Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00426.
    >> Share

  745. LIANG MI, Simons JL, Herbey I, Wall JA, et al
    Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00493.
    >> Share


  746. The implications of the loss of abortion services from the perspective of the gynecologic cancer care team.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00491.
    >> Share

  747. BARRINGTON DA, Meade CE, Cosgrove CM, Cohn DE, et al
    Racial and ethnic disparities in readmission risk following the surgical management of endometrial cancer.
    Gynecol Oncol. 2022 Jul 23. pii: S0090-8258(22)00486.
    >> Share

  748. SHALOWITZ DI, Charlton ME
    The road to geographic equity in access to gynecologic cancer care.
    Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00490.
    >> Share

  749. LEITAO MM JR, Zhou QC, Brandt B, Iasonos A, et al
    The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes.
    Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00434.
    >> Share

  750. LEVINE MD, Barrington DA, Hampel H, Goodfellow PJ, et al
    Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations.
    Gynecol Oncol. 2022 Jul 20. pii: S0090-8258(22)00488.
    >> Share

  751. LI H, Wang S, Liu Y, Wang T, et al
    Prophylactic extended-field irradiation for locally advanced cervical cancer.
    Gynecol Oncol. 2022 Jul 19. pii: S0090-8258(22)00481.
    >> Share

  752. TUCKER K, Sullivan S, Deal AM, Allman K, et al
    A prospective randomized trial of standard versus multimedia-supplemented counseling in patients undergoing endometrial cancer staging surgery.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00485.
    >> Share

  753. ALHILLI MM, Schold JD, Kelley J, Tang AS, et al
    Preoperative assessment using the five-factor modified frailty index: A call for standardized preoperative assessment and prehabilitation services in gynecologic oncology.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00435.
    >> Share

  754. KIM SI, Kim JH, Noh JJ, Kim SH, et al
    Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00483.
    >> Share

  755. CHASE DM, Marin MR, Backes F, Han S, et al
    Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
    Gynecol Oncol. 2022 Jul 15. pii: S0090-8258(22)00432.
    >> Share

  756. BENICHOU J, Schwall C, Sastre-Garau X, Mereaux J, et al
    Impact of the new molecular classification of endometrial cancer: A French cohort study.
    Gynecol Oncol. 2022 Jul 14. pii: S0090-8258(22)00484.
    >> Share

  757. HARE CJ, Crangle C, McGarragle K, Ferguson SE, et al
    Change in cancer-related fatigue over time predict health-related quality of life in ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00433.
    >> Share

  758. PITIYARACHCHI O, Friedlander M, Java JJ, Chan JK, et al
    What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (>/=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemothera
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00436.
    >> Share

  759. O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
    Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00405.
    >> Share

  760. PIEDIMONTE S, Bernardini MQ, Ding A, Laframboise S, et al
    Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
    Gynecol Oncol. 2022 Jul 9. pii: S0090-8258(22)00430.
    >> Share

  761. MCDONALD V, Wang Y, Patel A, Betcher R, et al
    Laparoscopic guided liposomal bupivacaine injection compared to transversus abdominus plane block for postoperative pain after robotic gynecologic oncology surgery.
    Gynecol Oncol. 2022 Jul 8. pii: S0090-8258(22)00406.
    >> Share

  762. CADOO K, Simpkins F, Mathews C, Liu YL, et al
    Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Gynecol Oncol. 2022 Jul 5. pii: S0090-8258(22)00421.
    >> Share

  763. TSENG JH, Bristow RE
    Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles.
    Gynecol Oncol. 2022;166:5-7.
    >> Share

  764. HANDLEY KF, Sood AK, Molin GZD, Westin SN, et al
    Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
    Gynecol Oncol. 2022;166:50-56.
    >> Share

  765. MOKHTECH M, Gao SJ, Kassick M, Menderes G, et al
    Declining use of inguinofemoral lymphadenectomy in the treatment of clinically negative, pathologic node positive vulvar cancer.
    Gynecol Oncol. 2022;166:61-68.
    >> Share

  766. O'CEARBHAILL RE, Perez-Fidalgo JA, Monk BJ, Tusquets I, et al
    Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
    Gynecol Oncol. 2022;166:36-43.
    >> Share

  767. NELSON G
    Social media in gynecologic oncology: A new frontier.
    Gynecol Oncol. 2022;166:3-4.
    >> Share

  768. GEHRIG PA, Farley J
    Introducing a new series in Gynecologic Oncology: Health equity in gynecologic oncology research.
    Gynecol Oncol. 2022;166:1-2.
    >> Share

  769. CHERSTON C, Yoh K, Huang Y, Melamed A, et al
    Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer.
    Gynecol Oncol. 2022 Jul 1. pii: S0090-8258(22)00427.
    >> Share

    June 2022
  770. LIU K, Zhu Y, Zhou Y, Zhang Y, et al
    Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00419.
    >> Share

  771. MUNOZ JL, Blankenship LM, Ramsey PS, McCann GA, et al
    Importance of the gynecologic oncologist in management of cesarean hysterectomy for Placenta Accreta Spectrum (PAS).
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00429.
    >> Share

  772. SY F, Greuel M, Winkler V, Bussmann H, et al
    Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00416.
    >> Share

  773. WALL JA, Lipking K, Smith HJ, Huh WK, et al
    Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
    Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
    >> Share

  774. ROGOWSKI P, Rottler M, Walter F, Saicic S, et al
    Clinical outcome of combined intracavitary / interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer.
    Gynecol Oncol. 2022 Jun 25. pii: S0090-8258(22)00423.
    >> Share

  775. BACORRO W, Baldivia K, Yu KK, Mariano J, et al
    Outcomes with definitive radiotherapy among patients with locally advanced cervical cancer with relative or absolute contraindications to cisplatin: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jun 24. pii: S0090-8258(22)00422.
    >> Share

  776. HEFFERNAN K, Nikitas FS, Shukla U, Camejo HS, et al
    Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
    Gynecol Oncol. 2022 Jun 22. pii: S0090-8258(22)00415.
    >> Share

  777. DICKEN BJ, Billmire DF, Rich B, Hazard FK, et al
    Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00417.
    >> Share

  778. RASMUSSEN CL, Thomsen LT, Baandrup L, Franzmann MB, et al
    Changes in HPV prevalence in Danish women with vulvar cancer during 28 years - A nationwide study of >1300 cancer cases.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00418.
    >> Share

  779. KEUNECKE C, Kulbe H, Dreher F, Taube ET, et al
    Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00414.
    >> Share

  780. AO M, Zheng D, Wang J, Gu X, et al
    Corrigendum to "Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia" [Gynecologic Oncology, Volume 162, Issue 3, September 2021, Pages 584-589].
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00411.
    >> Share

  781. KIM NR, Lee AJ, Yang EJ, So KA, et al
    Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00404.
    >> Share

  782. BOGANI G, Di Donato V, Papadia A, Buda A, et al
    Evaluating long-term outcomes of three approaches to retroperitoneal staging in endometrial cancer.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00407.
    >> Share

  783. CAMPBELL R, Costa DSJ, Stockler MR, Lee YC, et al
    Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
    Gynecol Oncol. 2022 Jun 16. pii: S0090-8258(22)00335.
    >> Share

  784. JERNIGAN A, Farley J, Walsh C
    Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer.
    Gynecol Oncol. 2022 Jun 15. pii: S0090-8258(22)00410.
    >> Share

  785. NAKAMURA K, Shigeyasu K, Okamoto K, Matsuoka H, et al
    ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer.
    Gynecol Oncol. 2022 Jun 10. pii: S0090-8258(22)00337.
    >> Share

  786. HEALD B, Mokhtary S, Nielsen SM, Rojahn S, et al
    Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
    Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00334.
    >> Share

  787. SCHIFF JP, Mintz R, Cohen AC, Huang Y, et al
    Overall survival in patients with FIGO stage IVA cervical cancer.
    Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00333.
    >> Share

  788. HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
    OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
    Gynecol Oncol. 2022 Jun 8. pii: S0090-8258(22)00331.
    >> Share

  789. LOF P, van de Vrie R, Korse CM, van Gent MDJM, et al
    Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00336.
    >> Share

  790. ZHOU N, Cui Y, Zhu R, Kuang Y, et al
    Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00306.
    >> Share

  791. HORSBOL TA, Kjaer SK, Andersen EW, Ammitzboll G, et al
    Use of hypnotics among women diagnosed with cervical cancer - A population-based cohort study.
    Gynecol Oncol. 2022 Jun 6. pii: S0090-8258(22)00330.
    >> Share

  792. NASIOUDIS D, Mastroyannis SA, Ko EM, Haggerty AF, et al
    Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
    Gynecol Oncol. 2022 Jun 3. pii: S0090-8258(22)00314.
    >> Share

  793. DIGGS A, Sia TY, Huang Y, Gockley A, et al
    Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
    Gynecol Oncol. 2022 Jun 2. pii: S0090-8258(22)00329.
    >> Share

  794. GERSHENSON DM, Sun CC, Westin SN, Eyada M, et al
    The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
    Gynecol Oncol. 2022;165:560-567.
    >> Share

  795. MARTIN AL, Sinha S, Peres LC, Hakam A, et al
    The impact of distance to closest negative margin on survival after pelvic exenteration.
    Gynecol Oncol. 2022;165:514-521.
    >> Share

  796. SCHNACK TH, Froeding LP, Kristensen E, Niemann I, et al
    Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study.
    Gynecol Oncol. 2022;165:420-427.
    >> Share

  797. HOU X, Zhai Y, Hu K, Liu CJ, et al
    Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
    Gynecol Oncol. 2022;165:552-559.
    >> Share

  798. FELIX AS, Addison D
    The intersection of gynecologic cancer, obesity, and cardiovascular disease.
    Gynecol Oncol. 2022;165:403-404.
    >> Share

  799. NG AP, Sanaiha Y, Verma A, Lee C, et al
    Insurance-based disparities and risk of financial toxicity among patients undergoing gynecologic cancer operations.
    Gynecol Oncol. 2022 Jun 1. pii: S0090-8258(22)00328.
    >> Share

    May 2022
  800. YADAV G, Roque DM, Bellone S, Manavella DD, et al
    Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
    Gynecol Oncol. 2022 May 28. pii: S0090-8258(22)00332.
    >> Share

  801. PIEDIMONTE S, Pond GR, Plante M, Nelson G, et al
    Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study.
    Gynecol Oncol. 2022 May 26. pii: S0090-8258(22)00310.
    >> Share

  802. GORGEU V, Borghese B, Koual M, Just PA, et al
    Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort.
    Gynecol Oncol. 2022 May 25. pii: S0090-8258(22)00321.
    >> Share

  803. NOLIN AC, Tian C, Hamilton CA, Casablanca Y, et al
    Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning.
    Gynecol Oncol. 2022 May 24. pii: S0090-8258(22)00312.
    >> Share

  804. BROEKMAN KE, van der Aa MA, Nijman HW, Jalving M, et al
    End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00258.
    >> Share

  805. GENNARI P, Tchaikovski S, Meszaros J, Gerken M, et al
    Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00313.
    >> Share

  806. MAH SJ, Anpalagan T, Marcucci M, Eiriksson L, et al
    The five-factor modified frailty index predicts adverse postoperative and chemotherapy outcomes in gynecologic oncology.
    Gynecol Oncol. 2022 May 20. pii: S0090-8258(22)00311.
    >> Share

  807. TYMON-ROSARIO JR, Manara P, Manavella DD, Bellone S, et al
    Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Gynecol Oncol. 2022 May 19. pii: S0090-8258(22)00305.
    >> Share

  808. MARSH LA, Aviki EM, Wright JD, Chen L, et al
    Sentinel lymph node mapping for endometrial cancer: Opportunity for medical waste reform.
    Gynecol Oncol. 2022 May 18. pii: S0090-8258(22)00308.
    >> Share

  809. ZHOU S, Liu S, Tian G, Zhao L, et al
    KLK5 is associated with the radioresistance, aggression, and progression of cervical cancer.
    Gynecol Oncol. 2022 May 17. pii: S0090-8258(22)00309.
    >> Share

  810. WANG CC, Al-Rubaye R, Tran V, Montemorano L, et al
    Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00307.
    >> Share

  811. HINCHCLIFF E, Westin SN, Herzog TJ
    State of the science: Contemporary front-line treatment of advanced ovarian cancer.
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00275.
    >> Share

  812. ANGELES MA, Hernandez A, Perez-Benavente A, Cabarrou B, et al
    The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2022 May 11. pii: S0090-8258(22)00278.
    >> Share

  813. GUIDA F, Dioun S, Fagotti A, Melamed A, et al
    Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022 May 9. pii: S0090-8258(22)00218.
    >> Share

  814. MCKINNISH TR, Greenwade MM, Wilkinson-Ryan I, Schwarz JK, et al
    Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography.
    Gynecol Oncol. 2022 May 7. pii: S0090-8258(22)00259.
    >> Share